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Thesis abstract 
Background— Antibiotics are inappropriately prescribed for many acute 
respiratory infections (ARIs) in primary care, for which they offer marginal 
benefits. This use of antibiotics is an important contribution to the worldwide 
problem of antibiotic resistance. Consultations between clinicians and patients 
with ARIs are well-suited for shared decision making (SDM) because of the 
antibiotic benefit-harm trade-off. However, little research has analysed the extent 
and nature of SDM in consultations in the context of ARIs, including what and 
how antibiotic benefits and harms are communicated. There is also limited 
research that has explored patients’ understanding of antibiotic resistance, its 
consequences, or whether patients consider its threat when deciding whether to 
use antibiotics for ARIs. 
Aims— This thesis aimed to explore: patient-clinician communication, including 
the use of SDM, of antibiotic benefits and harms (including antibiotic resistance 
as one of the harms during ARI consultations); patients’ understanding of 
antibiotic resistance and aspects of it (such as resistance reversibility and 
resistance spread among family members); and how these influence patients’ 
attitudes towards antibiotic use. Investigating these aims also required updating 
the current evidence about resistance development and decay by performing a 
systematic review. 
Methods— Four interrelated studies were conducted. Study 1 was an 
observational study in Australian general practices, nested within an ongoing 
cluster randomised trial of patient decision aids. In this study, consultations were 
audio-recorded, and the extent and nature of SDM in consultations between 
general practitioners (GPs) and patients with ARIs were subsequently analysed. 
Antibiotic benefits and harms communication, with and without the use of patient 
decision aids, was also explored. Study 2 was a qualitative study which used 
semi-structured interviews to explore patients’ understanding of antibiotic 
resistance, and related aspects, in a sub-sample of patients with ARIs who 
presented to GPs in Study 1. Study 3 was a systematic review and meta-analysis 
that examined the development and decay of antibiotic resistance in community 
patients after antibiotic use. This review was hampered by poor reporting, which 
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led to quantitative analysis (Study 4) that examined the quality of reporting of 
studies included in Study 3 using checklists developed from existing reporting 
guidelines. 
Results— Study 1 analysed 36 GP-patient consultations and found the extent of 
observer-assessed SDM between GPs and patients with ARIs was generally low 
(mean (SD) total observing patient involvement in decision making (OPTION12) 
score= 29.4 (12.5; 100-point scale). When patient decision aids were used (n=15 
consultations), a balanced discussion of antibiotic benefits and harms occurred 
more often and was more comprehensive, with antibiotic resistance mentioned in 
10 (67%) of these consultations. When decision aids were not used (n=21), 
antibiotic harms were rarely mentioned (n=1, 5%) and antibiotic resistance was 
never mentioned.  
Study 2 revealed five key themes about people’s understanding and 
consideration of antibiotic resistance: 1) antibiotic use is seen as the main cause 
of resistance, but what it is that becomes resistant is poorly understood; 2) 
resistance is perceived as a future 'big problem' for the community, with little 
appreciation of the individual impact of, or contribution to it; 3) poor awareness 
that resistance can spread between family members, but concern that it can; 4) 
low awareness that resistance can decay with time and variable impact of this 
knowledge on attitudes towards future antibiotic use; and 5) antibiotics are 
perceived as sometimes necessary, with some awareness and consideration of 
their harms.  
The systematic review (Study 3) included 25 studies (16,353 children and 1,461 
adults). The review showed that antibiotic resistance in Streptococcus 
pneumoniae initially increased fourfold after penicillin-class antibiotic exposure, 
but fell after one month (OR 1.7, 95% CI 1.3–2.1). For cephalosporins, the odds 
of isolating resistant bacteria was lower than for penicillins directly after exposure, 
but after one month returned to similar odds as it did for the penicillins. Macrolides 
were also associated with increased antibiotic resistance immediately after use, 
which persisted for at least three months (OR 8.1, 95% CI 4.6–14.2, from 
controlled studies and OR 2.3, 95% CI 0.6–9.4, from time-series studies). 
Resistance in Haemophilus influenzae after penicillins was not significantly 
increased initially, but was at one month (OR 3.4, 95% CI 1.5–7.6), before falling 
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to insignificant levels by three months. Data at three months was sparse for 
cephalosporins and macrolides.  
Study 4 showed varied reporting quality of studies included in the previous 
systematic review. The mean percentage (SD, range) of studies that adequately 
described all the checklist items was 59% for RCTs (14%, 36%–84%) and 52% 
for prospective cohort studies (17%, 13%–70%). Aspects of the studies, such as 
the sampling procedures used, and rationale for the study, were described in 
most studies, although specific details (such as about blinding, and the actual 
incidence of resistant and susceptible isolates analysed at each time-point) were 
missing in many. 
Conclusions and Implications— These studies highlighted the potential benefits 
that would arise from an increase in the proportion of consultations between 
clinicians and patients with ARIs in which SDM occurs. A balanced discussion, 
including how resistance is a potential harm of antibiotics, and what the possible 
consequences of this are, but that resistance decays with time (even if faster than 
previously reported), might lead to better engagement with patients about 
antibiotics. Patient decision aids are one method of assisting in this. Overall, 
addressing this need may reduce patients’ desire for, and use of, antibiotics for 
ARIs, but this needs empirically testing with further research. Moreover, research 
reporting antibiotic resistance needs to be improved at all levels from randomised 
trials to systematic reviews and other guiding documents. Establishing the need 
to consider the collection and aggregation of expert opinion to develop a globally 
endorsed reporting checklist for better reporting of antibiotic resistance in studies 
with prospective designs. Simultaneous measures to tackle antibiotic resistance, 
from communication to reporting, need to be implemented, to avoid living in a 
time when a simple prick injury could lead to death from an untreatable infection. 
Keywords 
Antibiotics, Antibiotic Resistance, Decision Making, Decision Support 
Techniques, Physician-Patient Relations, Primary Care, Respiratory Tract 
Infections, Resistance Decay 
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Chapter 1 
 
General Introduction 
 
“Mother, mother I am ill, 
Send for the doctor from over the hill; 
In comes the Doctor, 
In comes the Nurse, 
In comes the lady with 
the alligator purse. 
Penicillin says the Doctor, 
Penicillin says the Nurse, 
Penicillin says the lady with 
the alligator purse.”  
 
-Lilliput magazine version of an old skipping song   
Chapter 1: General Introduction 
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Background 
Antibiotic resistance occurs when bacteria become resistant to antibiotic 
treatment (1). The rise of antibiotic resistance means that effective and 
inexpensive antibiotic treatment for simple infections is being lost (2), leading us 
towards a post-antibiotic era (3). In the year 2050, 10 million people are expected 
to die as a direct result of antibiotic resistance, exceeding the number of people 
expected to die from cancer or road traffic accidents (4). This makes antibiotic 
resistance one of the world’s most threatening public health crises.  
Antibiotic use is the main driver of resistance (5-7). In healthcare, the 
inappropriate use of antibiotics, such as for conditions where there is minimal or 
no benefit from their use, is contributing to an increase in resistance rates (8). In 
Australia, over 30 million prescriptions for antimicrobials were dispensed in 2015 
(9, 10). The majority of these were prescribed in primary care, and in this setting, 
the most common indication is for ARIs. Australian clinicians prescribe antibiotics 
for more than 60% of patients with acute respiratory infections (ARIs) (9). 
There are common misperceptions about antibiotic use by both clinicians and 
patients. Clinicians often perceive that patients with ARIs who come to see them 
are expecting antibiotics (11, 12). Sometimes incorrectly, many patients 
overestimate the benefits of antibiotic treatment and underestimate the harms 
(13), believing that antibiotics provide benefit for all infections, including viral 
infections (14). These misperceptions are often not elicited, articulated or 
addressed in routine consultations.  
If the volume of antibiotic use for ARIs in primary care can be reduced through 
better communication and discussion about antibiotics (and their benefits and 
harms during routine clinical consultations), the impact on individuals, health 
systems and wider communities would be considerable.  
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Aims 
The core aim of this PhD is to explore patient-clinician communication of antibiotic 
benefits and harms for ARIs along with patients’ understanding of antibiotic 
resistance, its aspects such as resistance decay and spread among people who 
live in close proximity and how these influence patients’ attitudes towards 
antibiotic use. To fulfil this main aim, the following research questions, grouped 
into themes, were explored:  
Research questions  
Theme one: Patient-clinician communication about antibiotic treatment for ARIs 
1) What is the extent and nature of shared decision making in consultations 
between GPs and patients with ARIs, including if and how antibiotic benefits 
and harms are discussed? Does the discussion about antibiotic harms include 
antibiotic resistance? 
2) Are decision aids used in ARI consultations? Does the communication of 
antibiotic benefits and harms differ with and without the use of decision aids? 
3) What are patients’ perspectives of the decision-making process? 
Theme two: Patients’ understanding of aspects of antibiotic resistance and its 
influence on attitudes to antibiotic use 
4) What is patients’ understanding of antibiotic resistance directly after the 
decision-making point in a clinical encounter for ARI?  
5) What is patients’ understanding of antibiotic resistance aspects such as 
resistance decay and spread among people in close proximity? How have 
these influenced attitudes towards antibiotic use? 
Theme three: Evidence about resistance development and decay, including the 
reporting quality of antibiotic resistance studies 
6) What is the updated evidence about the development and time to resistance 
decay among community individuals following exposure to antibiotics? 
7) Does the behaviour of resistance decay differ among the different type of 
bacteria and antibiotic classes? 
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8) What is the completeness of reporting of prospective primary studies that 
have examined antibiotic use and resistance? 
Outline of the thesis 
Research questions 1-8 are presented as four separate but interrelated studies, 
with each study representing one chapter within the overall thesis. Two of these 
studies (Chapters 3 and 5) comprise work already published in peer-reviewed 
journals, and two others (Chapters 4 and 6) represent studies which are currently 
under review. The published chapters and associated references, along with 
each study’s supplementary materials, have been formatted consistently 
throughout the body of the thesis and the numbering of figures and tables kept 
continuous. 
Chapter outline 
Chapter 2 draws information from published trials, reviews, and other literature 
that have explored the problem of antibiotic resistance and its impact on the 
individual, community, and economy; antibiotic use and its communication in 
primary care; and the current evidence gaps in relevant antibiotic resistance 
research. 
Chapter 3 (Study 1; Questions 1, 2 and 3) describes an observational study that 
analysed audio-recordings of consultations between GPs and patients with ARIs. 
The study was nested within an ongoing randomised controlled trial (RCT) of 
decision aids for the most common ARIs (acute bronchitis, sore throat, acute otitis 
media). The study explored the nature and extent of shared decision making 
during routine clinical consultations, including communication about antibiotic 
benefits and harms, and how this differed if and when, decision aids were used 
during the consultations. 
Chapter 4 (Study 2; Questions 4 and 5) comprises a qualitative study conducted 
in a convenience sample of participants (recruited as part of Study 1) who had an 
ARI and were consulting a GP. The study explored patients’ understanding of 
antibiotic resistance and its aspects of it (such as spread among people who live 
in close proximity and antibiotic resistance decay) and how knowledge about 
antibiotic resistance influenced attitudes towards antibiotic use. 
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Chapter 5 (Study 3; Questions 6 and 7) presents a systematic review and meta-
analysis examining the development and decay of antibiotic resistance following 
individual exposure to antibiotics in primary care. Finally, Chapter 6 (Study 4; 
Question 8) describes an analysis of the reporting quality of antibiotic resistance 
among studies with prospective designs included in Study 3. 
Chapter 7 draws together the findings and novel contributions of the four research 
studies, within the broader scope of the whole thesis aims. Further, the chapter 
also discusses the implications of these findings for clinical practice, policymakers 
and identifies where future research efforts should be focused.  
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Chapter 2 
 
Literature Review 
 
“The thoughtless person playing with penicillin treatment is morally responsible for the 
death of the man who succumbs to infection with the penicillin-resistant organism.” 
 
-Sir Alexander Fleming   
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2.1 Antibiotic resistance 
Antibiotics have been critically important for treating infections since their 
discovery in the 1940s. However, in recent years, antibiotics are accelerating 
towards weakened effectiveness due to an increase in antibiotic resistance (1). 
Antibiotic resistance occurs when bacteria change in response to using 
antibiotics by selection, or induction, of genes to code for proteins that inactivate 
the antibiotic molecule (2). Antibiotic resistance has been growing rapidly over 
the past few decades (1, 3). It has emerged in all known antibiotics, and no new 
antibiotics have been developed to alleviate the resistance crisis (4).  
The emergence of antibiotic resistance 
Bacteria level 
Bacteria continuously evolve to resist antibiotics, as a direct result of the warfare 
between microbes (5, 6). Bacteria are selected to develop resistance 
mechanisms to overcome the action of the antimicrobial molecules within their 
environment (e.g. soil) (5, 6). This ‘intrinsic resistance’ describes the process by 
which genes that generate resistance already exist in the bacterial genome (7). 
These genes can be switched on by human, agricultural or animal use of 
antibiotics, or acquired either by mutation or gene transfer from another species 
of bacterium (so-called ‘acquired resistance’) (5, 6).  
Individual human level 
The human commensal microbiome consists of harmless bacteria present in 
body sites (e.g. the gastrointestinal tract (GIT) or skin). The microbiome is 
established as early as the first day in neonates (8). In the absence of selective 
pressure (e.g. antibiotic exposure), both resistant and susceptible bacteria co-
exist in harmony (9). With post-selective pressure from antibiotic use, resistance 
occurs when naturally susceptible bacteria acquire the genes encoding the 
resistance mechanism via mutation or genetic transfer from other resistant 
bacteria (through the methods of conjugation, transduction, or transformation) 
(10). Thus, antibiotic use by an individual increases the risk of resistance 
expression (11, 12) and decreases the microbiome population of susceptible 
bacteria.  
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Population level 
Millions of metric tonnes of antibiotics have been manufactured and utilised for a 
variety of human, animal, and agricultural uses, contributing significantly to 
antibiotic resistance selection (5-7). The link between antibiotic use and 
resistance is complex and incorporates multiple confounding factors (5, 13) 
including: 1) bacterial factors such as individual bacterial types, their mutation 
rates and pathogen host interaction; 2) human factors such as human-human 
transmission and vaccination; 3) and public health factors such as antibiotic 
resistance from food-producing animals, travel to high antibiotic-resistant 
destinations and sanitation (5).  
The spread of antibiotic resistance 
Antibiotic resistance can be spread by different means such as animal-human or 
human-human transfer (Fig. 1).  
Fig. 1. The spread of antibiotic resistance (14) 
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Animal-human transfer 
Giving antibiotics to animals kills many bacteria, leaving behind the resistant 
strains. Subsequently, animal-human transfer can occur through: 1) direct close 
human contact with farm animals (15) or animals in wildlife (16); 2) when food 
animals are slaughtered and processed, or from handling meat or other products 
contaminated with resistant bacteria (17); and 3) when irrigation water containing 
contaminated fertilisers or animal faeces is used on food crops (18).  
Human-human transfer 
Antibiotic resistance can be spread between humans either by contact inside 
healthcare settings (19), or community settings (20).  
Within hospitals, antibiotic resistant bacteria can transfer from one patient to 
another by healthcare workers with poor hand-hygiene practice, low 
hygiene/cleanliness of the hospital environment, or direct contact between 
hospitalised patients (19).  
Within community individuals, a recent study showed that fluoroquinolone 
treatment for patients with suspected urinary tract infections led to a two-fold 
increase in ciprofloxacin-resistant Enterobacteriaceae and an associated 
increased individual risk of colonisation for other household members (adjusted 
prevalence ratio (aPR)=1.8, 95% Confidence Interval (CI) 1.3–2.5) (21). 
Transmission between individuals can also occur through interaction within 
community-based settings such as nursing homes, schools, day care centres, 
through community activities such as sports participation, and by travel to high 
antibiotic resistance destinations (20). 
This continuous transfer cycle between hospitals and the community leads to the 
continuous load of antibiotic resistance at both ends. As most antibiotics are 
prescribed in the community, it is of paramount importance that efforts are 
directed towards reducing antibiotic use there (Fig. 2).  
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Fig. 2. Antibiotic resistance transfer cycle between hospitals and the community 
The impact of antibiotic resistance 
Antibiotic resistance has several negative impacts on individuals, healthcare 
systems, and the economy. 
Impacts on morbidity and mortality  
In the United States of America (USA) alone, the estimated number of infections 
caused by antibiotic resistance is about two million, coupled with 23,000 deaths 
each year (22). In the year 2050, 10 million people are expected to die as a direct 
result of resistance, exceeding the number of people expected to die from cancer 
or road traffic accidents (23). 
Patients with infections caused by resistant bacteria experience up to a two-fold 
increased rate of adverse outcomes compared with similar infections caused by 
susceptible strains (24). These patients also require the use of more toxic 
antibiotics for their treatment (25).  
Patients infected with resistant strains may often require additional surgical 
procedures such as revascularisation or debridement of the infected tissue (26) 
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and have a higher risk of complications (27), treatment failure, and transmission 
of infection to others (28). 
A systematic review which compared mortality associated with methicillin-
resistant (MRSA) and methicillin-susceptible Staphylococcus aureus 
bacteraemia found a significant increase in mortality associated with MRSA 
bacteraemia (Odds Ratio (OR)=1.93, 95% CI 1.52–2.42) (29). Similarly, strains 
of Enterobacter producing Extended Spectrum β-lactamase (ESBL) in patients 
with bacteraemia are associated with an increased risk of mortality (Risk Ratio 
(RR)=1.85, 95% CI 1.39–2.47), and increased incidence of delay in effective 
therapy (RR 5.56, 95% CI 2.94–10.51) (30).  
Increased morbidity and the length of hospitalisation stays reflect the short-term 
effects of antibiotic resistance on affected patients. However, there are also 
longer-term consequences, including effects on patients’ future health and 
possible isolation during future hospitalisation, and treatment with antibiotics, 
even if the patient’s infection is not caused by resistant strains (for example, if a 
patient with previous MRSA infection, develops a fever though to be associated 
with a bacterial infection, they will be treated with vancomycin). Furthermore, 
other non-clinical effects, include loss of work and family time (due to prolonged 
hospitalisation), and the emotional impact correlated with having an infection with 
resistant bacteria (24). 
Healthcare system impacts 
The emergence and spread of antibiotic resistance from the community into 
hospitals threaten the safety and efficacy of many medical procedures. In 
hospitalised patients with any infection, antimicrobial susceptibility testing is not 
common before treatment (24). Consequently, a mismatch can occur between 
the initial therapeutic agent and subsequent results of susceptibility testing, 
leading to delay of effective treatment (24). In a case-control study comparing 
clinical outcomes of patients with pneumonia caused by resistant organisms and 
those with infections caused by susceptible organisms, those with infection 
caused by resistant organisms were treated with effective antibiotics at a median 
of 72 hours after infection was suspected whereas patients infected with 
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susceptible strains received appropriate antibiotics after a median of 11.5 hours 
(31).  
Infection, or colonisation, with resistant strains has implications on the decision 
about the management of many common treatments, such as specific surgical 
procedures, implantable devices, and immunosuppressive therapy following 
transplantation operations. In the USA alone, it is estimated that between 38.7% 
and 50.9% of organisms which cause surgical site infections and 26.8% of 
organisms which cause infections after chemotherapy are resistant to standard 
antibiotics used for prophylaxis (32). For example, a 30% reduction in antibiotic 
prophylaxis efficacy in patients undergoing blood cancer chemotherapy, would 
cause an additional 683 deaths (32). Similarly, the same reduction in antibiotic 
prophylaxis efficacy in patients undergoing colorectal surgery, would cause an 
additional 4586 deaths (32).  
Patients infected with resistant strains require additional nursing care, 
consumables (e.g. gloves), diagnostic tests and imaging, and intensive care unit 
and post-acute care bed occupancy (33). In a retrospective review of patients 
with ESBL E. coli bloodstream infections (BSIs), the cost of antibiotic therapy 
increased 1.6-fold (mean ± SD, EUR 763 ± 437 versus 474 ± 270 for non-ESBL 
BSIs; p<0.001), the cost of nursing care increased 1.9-fold (mean ± SD, EUR 
3,894 ± 1,078 versus 2,001± 163 for non-ESBL BSIs; p=0.03), and the cost of 
other consumables (e.g. gloves) (mean ± SD, EUR 2,869 ± 2,676 versus 1,921 ± 
2,152 for non-ESBL BSIs; p= 0.02) (34).  
Economic impacts 
A systematic review of the cost impact of antibiotic resistant infections in inpatient 
care found a threefold increase in hospital costs among patients who had 
infections with multi-drug resistant organisms (MDRO) compared to non-MDRO 
strains (35). In a study in a teaching hospital in the USA which measured the 
medical and societal cost attributable to antibiotic resistant infections, the mean 
cost difference between patients with antibiotic resistant infections and matched 
controls was up to US$29,069 per patient (36). 
Antibiotic resistance is no longer limited to threatening individual health, as it 
poses huge economic costs if it remains unaddressed (23). In the USA alone, it 
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has been estimated that infections caused by antibiotic resistance cost the US 
health system US$20 billion, and US$35 billion in lost productivity, annually (22). 
By the year 2050, it is expected a cumulative cost to the global economic output 
of 100 trillion USD (23); or about 0.16% of the Gross Domestic Product (GDP) of 
all Organisation for Economic Co-operation and Development (OECD) countries 
(37). 
Is antibiotic resistance reversible? 
Antibiotic resistance can be reduced by decreasing antibiotic use. This is based 
on the assumption that a reduction in antibiotic use decreases selective pressure 
on resistance genes (5, 38, 39). However, the complexity of bacterial population 
dynamics and host-pathogen interaction make it difficult to predict resistance 
reversibility behaviour and time to decay.  
Bacterial level 
Two key factors explain the association between reduced antibiotic use and the 
reversibility or decay of antibiotic resistance: 1) the rate of appearance of resistant 
bacteria and the nature of resistance mechanisms and biological costs of 
resistance; and 2) the level of exposure to antibiotics and co-selection of 
resistance genes to more than one antibiotic (5, 38). Resistance traits are easily 
acquired by susceptible bacteria and may remain for some time without further 
exposure to antibiotic pressure (5). However, there is little empirical evidence 
about antibiotic resistance reversibility outside the laboratory in free living 
individuals. 
Individual level 
Resistance reversibility rates depend on bacterial factors besides individuals’ 
microbiome health (normal bacterial flora) and the amount of antibiotic exposure 
(38). Studies of resistance decay in individuals were systematically reviewed in 
2010 (12). The review found that resistant bacteria were detectable among 
commensals as long as 12 months after any antibiotic use, decaying 
exponentially from the maximum level directly after antibiotic use. However, there 
are methodological concerns with this review; specifically, the review combined 
data from prospective and retrospective studies. Using studies with retrospective 
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designs precludes the reporting of resistance at specific time points, which 
substantially reduces their contribution to estimating resistance decay. This 
suggests the current evidence should be updated, using synthesised evidence 
from only studies with prospective designs. Similarly, the rate of resistance decay 
between different bacteria, and following exposure to different antibiotic classes, 
have not been studied. Chapter 5 of this thesis reports on the findings from Study 
3 that investigated this research gap. 
This complexity of resistance reversibility makes a prediction about its decay at 
the bacterial level difficult. However, reducing antibiotic use by individuals will 
delay the emergence of antibiotic resistance and decrease the load of resistance 
within the community. 
2.2 Antibiotic use in primary care 
The alarm was raised as early as the discovery of penicillin that antibiotics could 
be overused when Sir Alexander Fleming (who discovered penicillin) himself 
pointed out that “The time may come when penicillin can be bought by anyone in 
the shops.” (40). One major driver of antibiotic resistance is the high volume of 
antibiotic use (41-43). In healthcare, the inappropriate use of antibiotics, 
especially for conditions where there is no or minimal benefit from their use, is 
contributing to rapidly increasing resistance rates (44). 
Australia’s antibiotic use is high compared to countries with similar 
socioeconomic status (45). In Australia, over 30 million prescriptions for 
antimicrobials were dispensed in 2015 (46). The majority of these were 
prescribed in primary care (46) where ARIs account for 10% of consultations (47). 
Australian clinicians prescribe antibiotics for more than 60% of patients with an 
ARI (46). Evidence from systematic reviews concludes that antibiotics have 
minimal benefit for most patients presenting with a sore throat (48), for preventing 
recurrent sore throat (49), for acute otitis media (AOM) (50), sinusitis (51, 52), 
cold (53), bronchitis (54), or laryngitis (55).  
In Australia, an estimated mean of 5.97 million (95% CI 5.69–6.24 million) cases 
of ARIs every year are managed in general practices using at least one antibiotic 
(56). If GPs adhered to the recommendations in Australian clinical practice 
guidelines (specifically for the management of AOM, acute pharyngitis or 
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tonsillitis, acute rhinosinusitis, and acute bronchitis/bronchiolitis), they would 
have prescribed antibiotics at 11–23% of the current prescribing rate (0.65-1.36 
million ARI cases per year) (56). Given the high level of antibiotic prescribing for 
ARIs in Australian primary care, focusing on reducing this level of prescribing has 
been the target of several strategies and initiatives and is the focus of the 
research in this thesis (56). 
The factors influencing antibiotic prescribing behaviour 
There are patient and clinician-related factors that influence clinicians’ antibiotic 
prescribing behaviour. 
Patient-related factors  
Many patients believe that antibiotics provide benefits for all infections, including 
viral infections (57, 58). In a systematic review which explored public knowledge 
and attitudes about antibiotics, 53.9% (95% CI 41.6–66.0%) of patients did not 
know that antibiotics cannot treat viral infections and 49.7% (95% CI 39.6–59.8%) 
did not know that antibiotics are not useful for flu and cold (59).  
Across nearly all medical treatments and tests, patients tend to overestimate the 
benefits and underestimate the harms (60). In a cross-sectional study of 
Australian parents (or caregivers) of children aged 1 ≤ 12 years, about their 
knowledge and expectations of antibiotic benefits and harms for ARIs, most 
parents (or caregivers) overestimated antibiotic benefits (61). Many participants 
believed that complications are less likely with antibiotic treatment and that 
antibiotics greatly reduce the length of the illness (e.g. 5.4 days mean reduction 
in acute cough compared to evidence-based estimates of <0.5 days). This 
contributes to both patients’ and parents’ expectations and requests of antibiotics 
for ARIs. 
Patients with ARIs are mostly seeking reassurance and information regarding 
their illness from their clinician (62, 63). In a survey of 1160 patients with ARIs 
visiting their GPs in the Netherlands, for patients who did not expect antibiotics, 
receiving reassurance was the only independent determinant of satisfaction 
(Adjusted OR 21.6, 95% CI 7.4–62.7). For patients who expected antibiotic 
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treatment, receiving reassurance (adjusted ORs of 4.7; 95% CI 1.9–11.9) was as 
important as being prescribed antibiotics (3.8; 95% CI 1.9–7.5) (62). 
Clinician-related factors  
Clinicians are the target for many interventions to reduce antibiotic prescribing; 
therefore, much research has investigated the factors that influence clinicians’ 
antibiotic prescribing (64). A summary of these is presented here. 
Clinicians’ clinical knowledge: Several studies have looked at the relationship 
between clinical knowledge and antibiotic overprescribing. In a systematic review 
exploring GPs’ antibiotic prescribing behaviours, 11 studies (31%) reported that 
clinicians’ indifference to learning more about reducing antibiotic prescribing in 
ARI management was directly related to antibiotic overprescribing (65).  
Diagnostic uncertainty and fear of disease progression: Clinicians with 
uncertainty about the diagnosis tend to prescribe more antibiotics to avoid 
missing treatable conditions ‘just in case’ and to avoid complications of bacterial 
illnesses (66-68). Patients’ clinical features also influence diagnostic uncertainty. 
A cross-sectional study of paediatricians and family practitioners found that 
clinicians were nearly seven times more likely to prescribe antibiotics if their 
patients looked unwell and twice as likely if the child had a fever above 38.5°C 
(69).  
Patients’ perceived demand for antibiotics: Clinicians are almost three times more 
likely to prescribe antibiotics for their patients if they believe patients expect them 
(70). In a recent systematic review, clinicians reported patient (or parent) 
pressure as a major influence on their antibiotic prescribing behaviour (67). Some 
clinicians feel prescribing antibiotics strengthens their therapeutic relationship 
with the patient (71) and sometimes do so to avoid confrontation (72). However, 
patients’ expectations are often misperceived by clinicians as many patients are 
more concerned about symptom relief and want treatment to alleviate the pain 
(63). 
Time pressure: Being busy can influence GPs to provide antibiotics, as some 
GPs see this as a fast way of establishing a sense of security, patient satisfaction 
and concluding the consultation rapidly (73, 74).  
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Strategies to reduce antibiotic prescribing in primary care 
This section presents some evidence-based strategies developed to reduce 
antibiotic prescribing, with emphasis on strategies which focus on improving the 
appropriateness of antibiotic prescribing for ARI management. 
Public-targeted strategies 
Nationwide mass media campaigns provide an opportunity to educate patients 
and the public about the aggravating crisis of antibiotic resistance and how they 
can help to reduce the severity of it. Several campaigns, consisting of extensive 
information dissemination across multiple channels, have been used in high-
income countries to promote appropriate antibiotic use. Some of these, as 
examined in observational studies, have led to a significant reduction in antibiotic 
use. For example, after nationwide mass media campaigns, antibiotic use 
declined by 26.5% in France between 2002-2007 (75) and by 36% in Belgium 
between 1999-2000 and 2006-2007 (76). The success of public campaigns 
partially depends on the availability of funding to deliver the message and needed 
are robust data collection methods to evaluate the outcome measures of each 
campaign (77). However, these campaigns have been very costly incurring 
expenses in the tens of millions of dollars. 
Clinician-targeted strategies 
Two main ways to target clinicians’ diagnostic uncertainty are by using diagnostic 
tests at point-of-care or through delayed prescribing.  
Point-of-care diagnostic tests 
Diagnostic tests within consultations may help clinicians to confirm the presence 
or absence of pathogenic bacteria causing the illness. Inflammatory cytokines 
trigger biomarkers of bacterial infection following tissue injury due to infectious 
(e.g. bacterial) and non-infectious conditions (e.g. trauma). With an increase in 
tissue damage or inflammation as a result of infection, the level of biomarkers in 
the blood increases. Test results can guide clinicians to the severity of the 
condition and allow them to identify which patients may benefit from antibiotic 
treatment and thus reduce unnecessary prescribing (78, 79). The two main point-
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of-care biomarkers of infection tests are C-reactive protein (CRP) and 
procalcitonin (PCT) (80, 81).  
A systematic review of the effectiveness of point-of-care CRP testing and 
antibiotic prescribing (82), found the testing significantly decreased antibiotic 
prescribing at index consultations (RR 0.78, 95% CI 0.66–0.92). Qualitative 
studies of clinicians’ attitudes towards and experience of CRP tests, reported 
positive attitudes by clinicians regarding the quick availability of the test results. 
Clinicians were also empowered to prescribe fewer antibiotics than they 
perceived necessary and their confidence with their antibiotic prescribing 
decisions increased (83, 84). In a qualitative study nested within a RCT of CRP 
testing and clinician training in communication skills, patients were satisfied with 
their treatment decision, despite not receiving antibiotics. Further, most patients 
described the CRP test as something that could distinguish between a virus and 
a bacterium and help indicate when antibiotics are needed (85). 
However, there are several challenges to the routine implementation of CRP 
testing in general practice. The reduction in antibiotic prescribing remains 
uncertain, and the test should be used as an adjunct to clinical examination, not 
as a substitute for it (82). In addition, CRP devices cost around AUD$1800-3000 
plus consumable costs per test, which creates a challenge for private general 
practices in Australia with no reimbursement for this investment (86). Additionally, 
education on the use of the test may be needed to avoid the unintended 
consequence of antibiotic overprescribing (87).  
Procalcitonin testing, as a biomarker of infection test, may help clinicians to 
decide when to initiate antibiotic treatment and when to stop it, reducing 
unnecessary antibiotic prescribing and decreasing the duration of antibiotic 
treatment (88). In a recent systematic review of the efficacy of using procalcitonin 
with patients with ARIs (89), procalcitonin guidance was associated with a 2.4-
day reduction in total antibiotic exposure (mean 8.1 days in the intervention 
group, compared to 5.7 days in the control group, 95% CI ‐2.71– ‐2.15, p< 0.001). 
Other candidates for point of care tests include white cell counts and anti-ASOT 
tests for streptococcal sore throat. 
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Delayed prescribing 
The concept of delayed prescribing is to provide patients with an antibiotic 
prescription along with the suggestion to wait a few days before dispensing and 
only if the patient does not get better or the course of illness deviates from the 
expected (90). In a Cochrane systematic review that evaluated delayed 
prescription of antibiotics versus no or immediate antibiotics for patients with ARIs 
(91), delayed prescribing reduced antibiotic use compared to immediate antibiotic 
use by approximately 62% (31% versus 93%), with no differences in complication 
rate. Patients who received a delayed prescription were more satisfied over those 
who received no antibiotics (OR 1.49, 95% CI 1.08–2.06). Clinicians may use this 
strategy to help overcome prescribing antibiotics for fear of disease progression 
and its complications. This is midway between providing immediate antibiotics 
and no antibiotics at all (92). 
Unfortunately, delayed prescribing is not widely used in general practices in 
Australia(92). The reasons are not clear why, but its implementation likely varies 
in different healthcare systems. Perhaps clinicians paid by fee-for-service (as in 
Australia) may have concerns about loss of income from not offering antibiotics 
immediately (93), although no research has investigated this. Another possible 
concern maybe the therapeutic vacuum left by not prescribing antibiotics. 
Patients may fill this vacuum with over-the-counter drugs, or complementary and 
alternative medicines (94). Although these products are not contributing to the 
resistance problem, they are mostly ineffective.  
Patient-clinician communication strategies 
Another strategy to reduce antibiotic use is to target patient-clinician 
communication within consultations. This addresses clinicians’ perceptions that 
patients expect antibiotics and tend to overestimate their benefits. Therefore, 
encouraging clinicians and patients to discuss the benefits and harms of 
antibiotics, the option of not treating with antibiotics, and the patient’s concerns 
and expectations may help patients to make an informed decision. Consequently, 
this may reduce inappropriate antibiotic prescribing in primary care. 
 
Chapter 2: Literature review 
[21] 
Shared decision making 
One strategy which shows promise for reducing antibiotic use is shared decision 
making (SDM). SDM is a process that involves clinicians and patients jointly 
participating in making a health decision. The decision-making occurs after the 
clinician and patient have discussed the options, the benefits and harms of each 
option, and considered the patient's values, preferences and circumstances (95, 
96). It is part of a patient-centred model of consultation where there is two-way 
information exchange channel between experts; the patient is an expert in his or 
her illness and values, and the clinician is an expert in disease diagnosis and 
providing appropriate treatment (97). Patients’ involvement in decision making 
can cause an increase in their satisfaction with the treatment decision, improved 
knowledge about benefits and harms of the available treatment options, a 
reduction in decisional conflict, and an opportunity to incorporate their values and 
preferences into clinical decisions (98, 99). 
Despite the benefits of SDM, there are several misconceptions about it and 
challenges to its implementation in practice. It is commonly believed that 
participation in SDM will lead to longer consultations, despite a recent systematic 
review showing no increase in consultation duration when SDM occurred (100). 
Another is clinicians’ perceived assumption that patients do not want, or are not 
able, to participate in making clinical decisions. This assumption was explored in 
several studies and systematically reviewed in 2012, where researchers found 
that in 71% of the studies conducted in or after 2000, most patients preferred 
sharing decisions with physicians (101).  
SDM can be facilitated by using decision support tools. These tools can take 
several formats such as decision aids, option grids, decision boxes, question 
prompt lists or evidence summaries (98). A Cochrane systematic review of the 
effects of decision aids for people facing treatment or screening decisions, found 
that patients exposed to decision aids had higher knowledge scores compared to 
those who received usual care (mean difference= 13.27/100; 95% CI 11.32–
15.23) and were more likely to have accurate risk perceptions (RR= 2.10; 95% 
CI 1.66–2.66) (99). 
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Shared decision making and antibiotic prescribing 
Consultations for ARIs are especially suitable for shared decision making, 
because of 1) people’s misperceptions of the need for and benefits of antibiotics 
and their underestimation of harms (61); 2) the delicate balance between benefits 
and harms, as there are marginal benefits and harms of antibiotics for ARIs; and 
3) the tendency of some GPs to avoid exploring and managing patients’ 
expectations about antibiotics. One method of executing this is to use “running 
commentaries” to set out these benefits and harms (102).  
A systematic review found that interventions which facilitated SDM for 
consultations with patients with ARIs in primary care (103), significantly reduced 
short-term antibiotic prescribing, at or immediately after, the index consultation 
(47% in intervention groups to 29% in usual care; RR= 0.61, 95% CI 0.55–0.68; 
p< 0.001). This reduction in prescribing occurred without an increase in re-
consultation rates (RR= 0.87, 95% CI 0.74–1.03) or decrease in patients’ 
satisfaction (RR= 0.86, 95% CI 0.57–1.30). However, a long-term reduction in 
antibiotic prescribing for ARIs was not significantly reduced (RR= 0.74, 95% CI 
0.49–1.11; p= 0.14).  
Our research team has developed brief decision aids which target three common 
ARIs (sore throat, acute bronchitis, and acute otitis media) seen in general 
practice (See Supplementary Materials 1-3 published with Study 1 Chapter 3). 
The effectiveness of these decision aids was evaluated in a RCT with parents of 
children aged 1-16 years in a hypothetical illness scenario (104). More parents 
who received a decision aid made an informed choice (57%) compared with those 
who received standard written information (29%) (mean difference 28%, 95% CI 
11%–45%, p< 0.01) and had higher total knowledge (mean difference 2.8, 95% 
CI 2.2–3.5, p< 0.01; 10-item scale) (104). However, this study used a hypothetical 
illness, and, therefore, the effect in real ARI consultations needs to be evaluated. 
To this end, a cluster randomised trial is underway in Australia to determine 
whether compared to usual care, these decision aids and a brief training package 
for the GPs (a 15-minute video explaining SDM and modelling how to use a 
decision aid) reduce GPs’ antibiotic dispensing rate (Australian New Zealand 
Clinical Trials Registry (ANZCTR) number: ACTRN12616000644460) (105). 
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To improve the appropriateness of antibiotic prescribing, an in-depth 
understanding of the extent and nature of SDM within ARI consultations is 
important, including if and how antibiotic benefits and harms are discussed, 
whether decision aids are used, and if so, whether they are integrated within 
clinical encounters. Although antibiotic resistance is one harm of using antibiotics, 
it is an ‘unusual harm’ as it does not affect individuals during their current illness 
(but may affect the course of treatments for their future illnesses of the same or 
other infections). Moreover, it has additional societal harms with the potential 
transmission of antibiotic resistance to other community individuals. It is unknown 
if and how antibiotic resistance is discussed during routine consultations, and 
how that impacts on clinicians’ discussion of antibiotic resistance, and patients’ 
reaction to the problem.  
Use of alternatives to antibiotics 
Antibiotic treatment is poor at relieving the symptoms which accompany ARIs 
(such as fever, pain, cough). Wanting relief from these symptoms is the most 
common reason for patients with ARIs to visit their clinician (63). A RCT to 
evaluate the effectiveness of a standardised and evidence-based educational 
seminar for GPs about antibiotic prescribing found that the more drugs used for 
symptomatic treatment, the fewer antibiotics were prescribed by GPs (106).  
In a survey of Australian parents, 63% of the sample reported using alternative 
treatments other than antibiotics for ARIs including analgesics, herbals, 
antihistamines, vitamins, honey, lozenges (61). The most commonly used over-
the-counter symptomatic treatments were analgesics and antipyretics (e.g. 
acetaminophen, ibuprofen). For most of the other reported alternative treatments, 
there is insufficient evidence to properly know their efficacy with symptomatic 
treatment for ARIs such as vitamin C (107, 108), honey (109), probiotics (110), 
steroids (111-113), or zinc (114). Further investigations are needed in large 
randomised trials to test these alternative treatments. 
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Exploring understanding of antibiotic resistance to inform patient-clinician 
communication in primary care consultations  
Understanding patients’ and clinicians’ knowledge and beliefs about antibiotic 
resistance, and reasons for using and not using antibiotics, can help inform 
interventions and public campaigns that aim to encourage appropriate antibiotic 
use.  
Patients’ knowledge and beliefs about antibiotic resistance 
Patients generally believe that they are at low risk from antibiotic resistance in the 
community (115). The reasons may be partially explained by not viewing 
antibiotic resistance as a direct harm from antibiotic use. In Australia, a recent 
cross-sectional study found that 49% of the 401 participants reported antibiotic 
resistance as one of the potential harms of using antibiotics (61), but the reasons 
were not explored (this was a survey). This area needs further research. 
Synthesised research that has explored the public’s understanding of resistance 
(54 studies with 55,225 participants) (115) showed that: 1) the public have 
misunderstandings about antibiotic resistance (e.g., they were confused by 
whether antibiotic resistance was a function of the bacteria or host), 2) many 
participants believed they do not contribute to the development of resistance and 
that others cause it, and 3) they believe they are at low risk from resistance and 
it will not affect them personally. The systematic review identified knowledge gaps 
in the literature (115). First, there were no studies which explored if people knew 
that antibiotic resistance is reversible, the timelines of this, and its impact on 
attitudes towards antibiotic use. Nor were there studies that explored patients’ 
knowledge of antibiotic resistance at the point of decision-making (instead, data 
came from hypothetical questions posed to healthy members of the public). 
These gaps are addressed in Study 2 (Chapter 4) of this thesis, in the context of 
antibiotic use for ARIs. 
Clinicians’ knowledge and beliefs about antibiotic resistance 
A systematic review which explored clinicians’ knowledge and beliefs about 
antibiotic resistance (57 studies, 11,593 clinicians) (116), found that many 
clinicians: 1) acknowledged the problem of antibiotic resistance, believing it was 
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a serious problem and that prescribing many antibiotics was the main cause (12); 
and 2) believed others, not themselves, caused the problem of antibiotic 
resistance, (other healthcare professionals or even patients), and several patient-
related factors contribute to antibiotic resistance (such as using antibiotics for a 
shorter duration than prescribed, or non-adherence). 
Antibiotic prescribing is influenced by clinicians’ knowledge and beliefs about 
antibiotic resistance. A systematic review which explored clinicians’ perceptions 
of factors influencing antibiotic prescribing, identified that clinicians’ 
misperceptions about the relationship between overprescribing and antibiotic 
resistance were a major factor influencing antibiotic prescribing, and they did not 
believe that their antibiotic prescribing was causing antibiotic resistance and that 
it is caused by others (65). One suggested solution is to link clinicians’ prescribing 
rates with local antibiotic resistance rates to demonstrate the causal relationship 
(117).  
2.3 Evidence gaps in antibiotic resistance research and its 
communication in primary care 
In 2015, the WHO launched a global action plan containing five strategic 
objectives: “1) to improve awareness and understanding of antimicrobial 
resistance; 2) to strengthen knowledge through surveillance and research; 3) to 
reduce the incidence of infection; 4) to optimise the use of antimicrobial agents; 
and 5) to ensure sustainable investment in countering antimicrobial resistance.” 
(118).  
Aligned with the strategic objectives of the WHO global action plan, particularly 
objectives one and four, this PhD aims to explore optimal communication of 
antibiotic resistance in primary care, with a focus on how antibiotic resistance and 
use are discussed within consultations between GPs and implications for 
decision-making. 
Patient-clinician communication about antibiotic treatment for ARIs 
As discussed earlier in this chapter, SDM is an effective strategy to reduce 
antibiotic prescribing for ARIs in primary care, but its uptake is low (103). This 
might be because adopting SDM in trials has been slow, extensive and 
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expensive. This may be a barrier to research translation. One strategy to facilitate 
SDM implementation within consultations may be using patient decision aids 
(99), because they are easier to implement in clinical practice. There has been 
little exploration of SDM in GP consultations for ARIs and whether and how 
antibiotic resistance is discussed during consultations. It is also unclear if patient 
decision aids, when provided, are used by GPs with patients with ARIs during 
their consultations and if their use influences discussion about resistance. These 
gaps are explored in Study 1 (Chapter 3). 
Patients’ understanding of aspects of antibiotic resistance and its influence on 
attitudes to antibiotic use  
Understanding patients’ beliefs about antibiotics can help to inform interventions 
and public health campaigns which encourage appropriate antibiotic use. Little 
research has explored patients’ understanding of resistance, the consequences 
of this, and whether patients consider the threat of resistance when deciding 
whether to use antibiotics. Perhaps, if people knew that antibiotic resistance is 
reversible, and it can be spread between those in close proximity (such as family 
members or households), this would influence their beliefs about, or use of 
antibiotics. These gaps are explored in Study 2 (Chapter 4). 
Evidence about resistance development and decay 
Several RCTs provide evidence that resistance is reversible, and that bacterial 
susceptibility returns to the pre-antibiotic exposure levels after almost one month 
post penicillin-class antibiotic exposure (119) and six months post macrolide-
class exposure (120). Studies reporting resistance decay following antibiotic 
exposure in the community were synthesised by one systematic review in 2010 
(12). However, as discussed earlier, a systematic review of these studies (that 
includes retrospective designs) may be flawed. This prompted a need to 
synthesise the evidence of resistance decay with an up-to-date review, using 
evidence from studies with only prospective designs, to explore whether the rate 
of resistance decay varies between the different antibiotic classes and bacteria. 
These gaps are further explored in Study 3 (Chapter 5). 
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The reporting quality of antibiotic resistance studies  
High-quality reporting of the trials which have investigated antibiotic resistance is 
needed to conduct accurate systematic reviews. While conducting Study 3, 
common issues with antibiotic resistance reporting in the prospective studies 
became apparent. Hence, Study 4 (Chapter 6) was conducted to analyse and 
characterise the reporting problems so steps towards improving this in future 
studies can be taken.   
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Preamble 
Despite growing acknowledgment of the need for shared decision making and its 
role in reducing antibiotic prescribing for ARIs, there has been little exploration if 
and how it occurs in GP consultations for ARIs. To improve communication about 
antibiotic benefits and harms, there is a need to know what happens during 
routine consultations and if decision aids, when provided, are a useful tool for 
improving the conversation. 
This chapter presents Study 1 which was published as an article entitled “Shared 
decision making and antibiotic benefit-harm conversations: an observational 
study of consultations between general practitioners and patients with acute 
respiratory infections”. 
Work arising from this chapter was featured in BMC series blog network October 
18, 2018, link: http://tinyurl.com/y8btr3ol, and was also presented as a poster at 
the 9th International Shared Decision Making Conference in Lyon, France 
between July 2nd and July 5th, 2017.  
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Abstract  
Background — Little research has examined whether shared decision making 
(SDM) occurs in consultations for acute respiratory infections (ARIs), including 
what, and how, antibiotic benefits and harms are discussed. We aimed to analyse 
the extent and nature of SDM in consultations between GPs and patients with 
ARIs, and explore communication with and without the use of patient decision 
aids. 
Methods — This was an observational study in Australian general practices, 
nested within a cluster randomised trial of decision aids (for acute otitis media 
[AOM], sore throat, acute bronchitis) designed for general practitioners (GPs) to 
use with patients, compared with usual care (no decision aids). Audio-recordings 
of consultations of a convenience sample of consenting patients seeing a GP for 
an ARI were independently analysed by two raters using the OPTION-12 
(observing patient involvement in decision making) scale (maximum score of 100) 
and 5 items (about communicating evidence) from the Assessing Communication 
about Evidence and Patient Preferences (ACEPP) tool (maximum score of 5). 
Patients also self-completed a questionnaire post-consultation that contained 
items from CollaboRATE-5 (perceptions of involvement in the decision-making 
process), a decisional conflict scale, and a decision self-efficacy scale. 
Descriptive statistics were calculated for each measure. 
Results — Thirty-six consultations, involving 13 GPs, were recorded (20 for 
bronchitis, 10 sore throat, 6 AOM). The mean (SD) total OPTION-12 score was 
29.4 (12.5; range 4-54), with item 12 (need to review decision) the highest 
(mean=3) and item 10 (eliciting patients’ preferred level of decision-making 
involvement) the lowest (mean=0.1). The mean (SD) total ACEPP score was 2 
(1.6), with the item about discussing benefits scoring highest. In consultations 
where a decision aid was used (15, 42%), compared to the 21 usual care 
consultations, mean observer-assessed SDM scores (OPTION-12, ACEPP 
scores) were higher and antibiotic harms mentioned in all (compared to only 1) 
consultations. Patients generally reported high decision involvement and self-
efficacy, and low decisional conflict. 
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Conclusions — The extent of observer-assessed SDM between GPs and patients 
with ARIs was generally low. Balanced discussion of antibiotic benefits and harms 
occurred more often when decision aids were used.  
Keywords— Decision Making, General Practice, Respiratory Tract Infections, 
Decision Support Techniques, Physician-Patient Relations  
Chapter 3: Patient-clinician communication about antibiotic treatment for ARIs 
 
[40] 
Background 
One of the main causes of increased antibiotic resistance is high levels of 
antibiotic use, with approximately 80% of antibiotic use occurring in the 
community (1). Within primary care, acute respiratory infections (ARIs) are one 
of the most common reasons for an antibiotic prescription, even though antibiotics 
provide only small benefit and can cause harms (2-5). 
General practitioners' (GP) antibiotic prescribing behaviours are influenced by 
many factors, including diagnostic uncertainty, perceived patient pressure for 
antibiotics, and the need to maintain a good relationship with patients (6-9). Many 
patients believe that antibiotics resolve symptoms, are necessary, and have no 
harms (10). These beliefs contribute to some patients expecting, and sometimes 
requesting, antibiotics (10-12). 
Shared decision making (SDM) is a process that involves clinicians and patients 
jointly participating in making a health decision, after having discussed the 
options and the benefits and harms of each option, and considered the patient's 
values, preferences and circumstances (13-15). For most ARIs, the choice about 
whether to treat with antibiotics, or not, is nearly at equipoise, with the benefits 
closely balanced by the harms. This makes consultations for ARIs ideally suited 
for SDM. When deciding about antibiotic use for ARIs, most patients want more 
involvement in the decision-making process and more opportunity to weigh up 
the benefits and harms of the options (16, 17). A recent systematic review found 
that interventions to facilitate SDM reduced antibiotic prescribing for ARIs in 
primary care, compared with usual care, from 47% to 29% (risk ratio of 0.61; 95% 
confidence interval 0.55 to 0.68) (18). However, there has been little exploration 
of the prevalence and nature of SDM in GP consultations for ARIs, including 
whether and how any patient decision aids may be used to facilitate SDM. 
In a sample of consultations (where some GPs had been provided with ARI 
decision aids), we aimed to: 1) analyse the extent and nature of SDM in 
consultations between GPs and patients with ARIs, including if and how antibiotic 
benefits and harms are discussed; 2) explore the use of patient decision aids in 
ARI consultations and the communication of antibiotic benefits and harms with 
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and without decision aids; and 3) explore patients’ perspectives of the decision-
making process. 
Methods 
Design  
This was an observational study that ran in parallel to an ongoing cluster 
randomised trial of three decision aids (for acute otitis media [AOM], acute sore 
throat, and acute bronchitis) and a brief GP SDM training package (19) 
(Australian New Zealand Clinical Trials Registry (ANZCTR) number: 
ACTRN12616000644460) 
Participants and setting  
For the trial, general practices were recruited from established GP research 
networks, primarily in southeast Queensland, Australia. Practices whose GPs 
had already consented for the trial or its pilot were invited to participate in, and 
provide written consent for, this additional study during 2017 (see Appendix 1 for 
GPs’ consent form and information sheet). Practices were not eligible if they had 
participated in any other study where the main intention was to reduce antibiotic 
prescribing for ARIs. Patients were eligible to participate if they met the following 
criteria: 1) adult or parent of a child consulting a GP with one of three ARIs (AOM, 
acute sore throat, acute bronchitis) for the first time for that illness episode; 2) 
able to understand and read English; and 3) provided written informed consent 
(see Appendix 2 for patients’ consent form and information sheet). 
Some GPs (in practices that had been randomised to the trial’s intervention group 
or had piloted the intervention) had previously been provided with: 1) three 
decision aids (one each for AOM, acute sore throat, and acute bronchitis), in 
printed form (single A4 page, double-sided and laminated) and in PDF 
(Supplementary Materials 1-3); and 2) a USB-drive containing a 15-minute video-
based SDM training package that explained what SDM is, its use in ARI 
consultations, and a consultation demonstrating use of one of the decision aids. 
These GPs were given the intervention package and encouraged to use the aids 
during consultations with patients with ARIs whenever they felt it was appropriate. 
No further instruction or encouragement to use the aids or SDM strategies 
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occurred. The GPs in practices randomised to the control group did not receive 
the training package or decision aids and continued providing their usual care. 
Procedure 
The exact procedure for recruiting patients varied according to each practice’s 
preference. On recruitment days, at some practices, one of us (MB) approached 
only patients who were waiting to see the GPs who were participating. In other 
practices, all waiting patients were approached and asked if they were waiting to 
see one of the participating GPs (GP names were listed). If so, we proceeded 
with recruitment. Patient eligibility was determined by asking the patients if they 
were suffering from one of the following symptoms (sore throat, cough, ear pain), 
and confirmed afterwards by the clinician. If the patient was diagnosed as having 
an illness other than an eligible ARI, the recording was deleted. After written 
informed consent was provided, an audio-recording device was handed to the 
GP who began recording just before the patient entered their consulting room. 
After patients left the room, they were given a short questionnaire (<5 minutes) 
to complete (see Appendix 3 for patient questionnaire). It contained basic 
demographic questions and items from tools to measure their perspectives of 
involvement in the decision-making process, decisional conflict, and confidence 
in decision-making (see section below on patients’ perspectives). 
Outcome measures 
The extent of SDM (observer-assessed): Each consultation recording was 
analysed, by listening to the audio-recordings, by two independent raters using 
two measures. One measure was the 12-item Observing Patient Involvement 
(OPTION-12) scale, which has good discriminative validity, concurrent validity, 
and interrater and intra-rater reliability (20, 21). It contains 12 items scored on a 
five-point scale: (0) the behaviour was not observed; (1) a minimal attempt is 
made; (2) the behaviour is observed with a minimal skill level; (3) the behaviour 
is executed to a good standard; and (4) the behaviour is executed to a high 
standard. Total scores were re-scaled to 0-100.  A second measure was 5 items 
(1 subscale) of the Assessing Communication about Evidence and Patient 
Preferences (ACEPP) tool. This was used as the OPTION scale does not 
specifically evaluate communication of the quantitative benefits and harms of the 
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options. It has good reliability and has been used previously to assess evidence 
communication in consultations (22, 23). The items rate clinicians’ performance 
in describing the benefits/harms in terms of patient outcomes, the likelihood of 
benefits/harms, and the evidence source. Items were scored as: the behaviour 
was not observed (0); behaviour was observed at a basic level (0.5); or observed 
to an extended level (1). 
To establish scoring reliability, three of us (MB, EG, TH) independently rated an 
initial sample of recordings and responses were discussed until agreement was 
reached. Two of us (MB, EG) independently rated the remainder. Any rating 
discrepancies were resolved by a third person (TH). The two raters also extracted 
verbatim any mention of antibiotic benefits and harms. 
Patients’ perspectives: Patients’ perceptions of their involvement in the decision-
making process were measured using the CollaboRATE-5 scale (score range 0 
to 5) (24, 25). It asks three questions about what occurred in the consultation: 1) 
deliberation of the health issue, 2) exploration of patient preferences, and 3) 
integration of patient preferences (25). The scale has demonstrated significant 
discriminative validity, excellent intra-rater reliability and concurrent validity with 
other measures of SDM (24). 
Decisional conflict is a condition of uncertainty about options involving trade-offs 
and potential for regret. It was measured using the 10-item low literacy decisional 
conflict scale (26). In this study, patients’ feelings conflict about whether they felt 
that their decision (using antibiotics or not) was the best for them was assessed. 
The scale has good validity and reliability (27). The low-literacy version uses a 
question-and-answer format with three response options (yes, no, unsure), with 
scoring from 0 (low decisional conflict) to 100 (high decisional conflict) (27). 
Patients’ confidence in decision-making was measured using four items from the 
decision self-efficacy scale (28), which has high  internal consistency (29). 
Scoring of each item is from 0 (not at all confident) to 100 (very confident). 
Data analysis 
We calculated descriptive statistics (mean, standard deviation, range) for each 
outcome measure. Data were analysed using IBM SPSS (version 23). Benefits 
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and harms of antibiotics mentioned were categorised into similar groups, by 
description level as per ACEPP scoring, and by whether a decision aid was used.  
We present the results for the whole sample in line with our original aims. 
However, to explore the impact of decision aids, we also present the data 
separately for those consultations in which a decision aid was used and not used, 
along with mean differences and 95% confidence intervals. 
Results 
Ten general practices (3 intervention, 5 control), involving 44 GPs, that had 
already consented to participate in the main trial or piloting of the decision aids 
(2 practices) by the time that recruitment for this study commenced were invited 
to participate in this additional study. Of these, 5 practices and 19 GPs provided 
consent. During the recruitment period, 208 patients were approached and 41 
met the inclusion criteria. Of these, 36 patients provided consent for the recording 
and 25 also agreed to complete the questionnaire. The main reason given for 
declining to complete the questionnaire was insufficient time. We recorded 36 
consultations, involving 13 GPs - 20 were for acute bronchitis, 10 for acute sore 
throat, and 6 for AOM. Patient, GP, and consultation characteristics are 
presented in Table 1. 
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Table 1. Characteristics of the GPs, patients, and consultations  
Characteristic N* (%) 
GP gender – female 11 (61) 
Patients 
 Adults (Patient or parent) 18 (50) 
  Female 15 (83) 
  Age in years - median (min-max) 36 (18-77) 
 Children 18 (50) 
  Female   7 (39) 
  Age in years – median (min-max)   2 (0.8-15) 
Condition 
  Acute bronchitis 20 
  Acute sore throat 10 
  Acute otitis media   6 
Decision aid used in the consultation  15 (42) 
Consultation duration (minutes) - median (min-max)   9 (4-31) 
Treatment decision (from analysis of consultation recording) 
 Antibiotics   3 
 Delayed prescribing   7 
 No antibiotics 26 
Treatment decision immediately post-consultation** (as reported by 
patients)  
  Antibiotics   5 
  No antibiotics 20 
*This is the number of consultations, GPs, or patients 
** Not all patients felt sufficiently decided to report their treatment decision during the 
post-consultation interview.  
 
The extent of observer-assessed SDM  
The mean (SD) total OPTION score was 29.4 (12.5; range 4-54) (on a 100-point 
scale). The two highest scoring items were Item 12 (clinician indicates the need 
to review the decision) (mean=3, SD=1.5) and Item 4 (clinician lists ‘options’) 
(mean=2.2, SD=1.5). The two lowest scoring items were Item 10 (clinician elicits 
patient’s preferred level of involvement in decision making) (mean=0.1, SD=0.3), 
and Item 11 (clinician indicates the need for a decision making) (mean=0.3, 
SD=0.5) (Fig. 3). The mean (SD) total ACEPP score was 2 (1.6) (on a 5-point 
scale), with Item 1 (clinician describes the treatment benefits) scoring the highest 
(mean=0.6, SD=0.5) (Fig. 4). 
In consultations in which a decision aid was used (n=15), the mean (SD) total 
OPTION score was 38.8 (6.5), compared to 22.7 (11.5) for those (n=21) in which 
an aid was not used - a mean difference of 16 (95% CI 9.4-22.7). Similarly, the 
mean (SD) ACEPP score in consultations where an aid was used was 3.8 (0.5) 
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which was higher than those which did not 0.8 (0.8) - a mean difference of 3 (95% 
CI 2.6-3.5). 
Discussion of antibiotic benefits and harms 
Table 2 contains verbatim examples of how antibiotic benefits and harms were 
presented within consultations, categorised by level of description. The three 
most commonly discussed harms were diarrhoea, rash, and antibiotic resistance. 
In the 21 consultations that did not use a decision aid, the potential harms were 
mentioned in only 1 consultation (with nausea mentioned). Conversely, in the 15 
consultations in which a decision aid was used, at least one harm was mentioned 
in all of them. Two harms were mentioned in 14 (93%) and 3 harms in 13 (87%) 
of these consultations. When benefits were discussed, those mentioned were: 
that antibiotics help patients’ symptoms resolve faster; and reduce symptom 
severity, and the chance of complications. Benefits and their likelihood were 
explained in all 15 of the consultations where a decision aid was used. Where 
aids were not used, benefits were mentioned in 7 (33%) of the 21 consultations, 
but the likelihood of benefits described in only 1.  
  
Fig. 3. Mean scores of OPTION 12 items 
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Fig. 4. Mean scores of ACEPP items about communication of benefits and harms 
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Table 2. Verbatim examples of how the benefits and harms of antibiotics for ARIs were presented by GPs within the consultations, 
grouped by level of description and whether a decision aid was used. 
Benefits of antibiotics Harms of antibiotics 
Side effects Resistance 
With 
decision 
aids 
(n= 15) 
Benefits mentioned in 15 (100%) of 
15 consultations 
Side-effects mentioned in 15 (100%) 
of 15 consultations 
Resistance mentioned in 10 (67%) of 
15 consultations 
Mentioned to an extended level 
(15/15) 
Examples: 
Mentioned to an extended level 
(7/15) 
Examples: 
Mentioned to an extended level 
(5/10) 
Examples:  
GP D-2-6 “All the evidence shows if 
we have somebody with middle ear 
infection like what we have got here 
now…if you don’t give any antibiotics 
the infection lasts about 3.5 days in 
total. If you give antibiotics it reduces 
that by 12 hours. It can cut off about 
12 hours of the symptoms by giving 
antibiotics, so giving antibiotics is of 
limited benefit” … “so, if we look at 
100 kids who don’t take antibiotics, 
84 will be better in 3 days. If we give 
antibiotics there is an extra 5 kids 
who would be better.” 
GP B-1-2 “Most sore throats get 
better somewhere between 2 and 7 
days and that is actually whether or 
not you get antibiotics. Even if it is a 
bacterial infection you get better 
without antibiotics. So the treatment 
options are to take antibiotics or to 
GP A-2-1 “What we are looking at over 
here is what the potential 
complications maybe with antibiotics. 
So people who do not take antibiotics, 
20 out of a 100 will have some other 
problems associated with the illness. 
Whether it be vomiting, diarrhoea or 
rash. Whereas if we give you 
antibiotics, you are more likely to have 
side effects or complications. So 7 
more people out of a 100 …will have 
these potential side effects of these 
antibiotics. There are also other harms 
with antibiotics which can be having 
an allergic reaction, it can be the cost 
of buying them, remembering to take 
them…” 
GP A-5-2 “The other concern as well 
is antibiotic resistance, meaning you 
know the long term implications, all the 
good bacteria in his system being 
exposed to antibiotics as well they can 
develop some resistance, so …[if] he 
got meningitis in the near time and 
needs antibiotics, taking some will not 
work, because of previous resistance” 
GP B-1-2 “one of the problems that a 
lot of the bacteria that we have had in 
the community for years is getting 
stronger and stronger and resisting the 
antibiotics that we have got. So we are 
finding this is why this shows here that 
only a few people finding any benefit 
from taking the antibiotics because 
there is more and more resistance in 
the community… but we are finding 
increasingly is that the more we use 
them for infections that your body 
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not take antibiotics … This is a graph 
that shows you how long a sore 
throat would last on average. So if 
you take antibiotics, generally the 
sore throat would last about 2.6 days 
so just over 2 and a half days. If you 
do not take antibiotics on average it 
will last about 3.3 days, so that 
means it last about 16 hours longer 
without the antibiotics.”     
could probably fight them by yourself, 
we are actually, unfortunately, 
breeding bacteria that become 
stronger and stronger… and 
unfortunately at this point of time we 
have bacteria that is resistant to 
everything we have got and there is 
nothing new on the horizon vastly 
different from what we have got”  
 Mentioned to a **basic level (8/15) 
Examples: 
Mentioned to a basic level (5/10) 
Examples: 
 GP D-2-4 “… the only problem is it 
increases the number of people who 
get rash, diarrhoea, another side 
effects because of the antibiotics…” 
 
GP A-3-1 “… but then you look at the 
side effects and we have got all these 
people who do not take antibiotics 
obviously no side effects… and in the 
antibiotics you get more side effects 
basically. So that’s each one of these 
little dots is someone who gets the 
side effect”   
GP D-2-9 “but in the big picture we are 
building on antibiotic resistance and 
you know we are coming to time where 
these things might not work for 
infections you got them to do”  
 
GP D-2-7 “… and then you worry about 
antibiotic resistance and stuff like that” 
 
 
Without 
decision 
aids 
(n=21) 
Benefits mentioned in 7 (33%) of 21 
consultations 
Side-effects mentioned in 1 (5%) of 
21 consultations 
Resistance was not mentioned in 
any consultations 
Mentioned to an extended level 
(5/7) 
Examples: 
No extended level mentions  
GP C-1-1 “The evidence is that 
middle ear infection gets better 12 
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hours to 24 hours earlier if you give 
antibiotics and the pain is better 12 to 
24 hours if you give antibiotics”   
Mentioned to a basic level (2/7) 
Examples: 
Mentioned to a basic level (1/1) 
Examples: 
 
GP F-1-5 “…in which case antibiotics 
won’t do anything to get you better 
quicker” 
GP F-2-1 “And antibiotics would just 
give him side effects and upset his 
tummy” 
 
 
*Extended level: The clinician explains the benefits or harms of antibiotic treatment in a manner that is clear, with elaboration on the likelihood of these 
occurring, **Basic level: The clinician lists at least some of the benefits or harms of antibiotic treatment 
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Patients’ perspectives of the consultation and decision-making process  
The mean (SD) CollaboRATE-5 score for all consultations was 3.8 (0.4), representing 
high perceived patient involvement in the decision-making process. The mean (SD) 
Decisional Conflict score was 3.2 (8), indicating a low level of decisional conflict. 
Participants had high confidence in the decision made, with a mean (SD) decision self-
efficacy scale score of 95 (10). There were minimal differences between the scores of 
patients who had, and had not, been presented with a decision aid during the 
consultation (Table 3). 
 
Table 3.  Mean (SD) scores of observer-assessed SDM scores and patients’ 
perspective of the consultation and decision-making process. 
Observer-assessed SDM scores (n= 36 consultations) 
 Total Mean (SD) score 
All GPs  
(n= 36) 
Usual 
Care  
(n= 21) 
Decision 
Aids  
(n= 15) 
OPTION-12 (0-100) 29.4 
(12.5) 
22.7 
(11.5) 
38.8 (6.5) 
ACEPP (0-5) 2 (1.6) 0.8 (0.8) 3.8 (0.5) 
 
Patients’ perspective scores of the consultation and decision-making 
process (n= 25 patients) 
 Mean (SD) 
All patients 
(n= 25) 
Usual 
Care  
(n= 16) 
Decision 
Aids  
(n= 9) 
CollaboRATE-5 mean encounter 
score (0-5) 
3.8 (0.4) 3.9 (0.3) 3.7 (0.5) 
Decisional Conflict Scale (0-100) 3.2 (8) 3.1 (7) 3.3 (10) 
Decisional Self-efficacy (0-100)  95 (9.9) 96.5 (6.8) 92.4 (13.9) 
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Discussion 
Summary 
Our analysis of consultations between GPs and patients with ARIs found the extent of 
observer-assessed SDM was generally low and the communication of antibiotic 
benefits and harms was also often suboptimal. In consultations in which patient 
decision aids were used, the discussion of antibiotic benefits and harms was more 
frequent and more comprehensive. When decision aids were not used, antibiotic 
harms were rarely mentioned, and antibiotic resistance was never mentioned. 
Strength and limitations 
Strengths of our study include minimising any bias from clinicians choosing which 
consultations to record as patient consent occurred before the consultations; two 
independent raters scoring the consultations; and obtaining patients’ perspectives. 
Limitations include the design (not a true randomised trial, although it is nested within 
one), which might have exaggerated the effects of the decision aids; the small number 
of consultations and that they may be non-representative; and GPs’ self-selection to 
participate in this additional study, which may have recruited those more confident and 
competent in SDM. The presence of the audio recorder in the consultation and the 
researcher in the waiting room may have resulted in performance bias, such as the 
Hawthorne effect, and inadvertently acted as a prompt for GPs to attempt or improve 
SDM. Also, results are limited to one country and clinicians participating may not be 
representative of those in other settings.  
Comparison with existing literature 
We know of no other studies that have objectively analysed the extent of SDM in GP-
patient consultations for ARIs. Although a recent systematic review (18) of trials whose   
interventions had aimed to increase SDM in ARI consultations in primary care found 
that these interventions decreased antibiotic prescribing, none of the 10 included trials 
actually objectively measured whether SDM improved as a result of the intervention.  
Similarly, low OPTION scores to those in this study have been reported in previous 
studies in different settings, such as outpatient cancer patients consulting their 
physicians (30), patients with back pain consulting their GPs (31), and patients 
consulting nutritionists about dietary treatment (32). In a systematic review of studies 
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that had used OPTION-12 to analyse consultations, OPTION Item 12 was one of the 
most consistently observed behaviours (33), and Item 10 score was very low, similar 
to our study.  
Implications for practice and research 
When decision aids were used the extent of SDM increased, including a large 
improvement in the frequency and quality of the conversation about antibiotic benefits 
and harms. Having the options with their pros and cons clearly listed in a decision aid 
may act as a reminder for GPs to discuss them with patients. The better discussion of 
antibiotic benefits and harms, including explaining the size and/or likelihood of them, 
is also likely due to the aids containing a very synthesized summary of the evidence 
about antibiotic benefits and harms. GPs may be unaware of the empirical benefits 
and harms data of antibiotics for ARIs. While no studies have examined GPs’ 
knowledge of antibiotic benefits and harms, a study of paediatricians found they 
overestimate antibiotic benefits for ARIs (34) and generally, clinicians tend to have 
poor knowledge of treatment benefits and harms, overestimate benefits and 
underestimate harms (35).  
Better benefit-harm perception by patients is necessary for informed decision making, 
and randomised trials have shown this improves when decision aids are used (36). In 
ARI consultations, improving patient benefit-harm perception is particularly important 
because the evidence shows near-equipoise in the benefits-harms balance, patients 
overestimate the benefits of antibiotics for ARIs (17, 37), and they rarely hear about 
the harms. Correcting these misperceptions may break the cycle of patient 
expectations of antibiotics as a driver of antibiotic prescribing.  
Antibiotic resistance is different from the side-effects that might typically be discussed 
by clinicians because it is not obviously an immediate or personal consequence for 
the individual patient. Many members of the public have misunderstandings about 
what antibiotic resistance is (38) and believe that it does not affect them (39). However, 
it is a global problem that can affect anyone, even if indirectly, and it needs confronting. 
Consultations in which antibiotics are being considered for common ARIs are an ideal 
time to discuss antibiotic resistance as part of the benefit-harm trade-off of using 
antibiotics because this is an area of very high consumption. We found many missed 
opportunities for discussions about this to occur. Even when resistance was 
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mentioned, discussion was usually brief and often not clear. Clinicians’ 
misunderstandings of antibiotic resistance have been reported in a systematic review 
(40). 
Patients perceived that they had high involvement in the decision, despite observer-
assessed SDM scores which were quite low. Reasons for this are not clear. Perhaps 
patients have not experienced consultations in which SDM was performed to a high 
level and they have low expectations of what patient involvement actually is, or 
perhaps the brief tool used with patients did not capture enough elements or enough 
similar elements that the observer-used measures did, such as whether benefits and 
harms were discussed. Patients also reported low decisional conflict and high 
confidence in their decision. This may reflect that the decision about whether to use 
an antibiotic for a minor illness is perceived by patients as a relatively simple one-off 
decision with low-stake harms. A trial of a decision aid and intense GP training to 
increase SDM for ARIs also reported low decisional conflict in patients in both control 
and intervention groups, with no statistically significant between-group difference (41).   
Conclusions 
This study highlights that in this convenience sample of patients with ARIs who were 
seeing a GP, some elements of SDM occurred during the consultation, but that there 
is need for improvements in the extent to which SDM occurs during such consultations, 
including how antibiotic benefits and harms are discussed. Patient decision aids may 
be part of the solution to improving this, but further research about their effect and how 
to support GPs to discuss antibiotic resistance with patients is needed. 
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Preamble 
The previous study found that the extent of observer-assessed SDM between 
GPs and patients with ARIs was generally low. It also found that a more balanced 
and comprehensive discussion of antibiotic benefits and harms, including 
antibiotic resistance, occurred when decision aids were used. Study 2 aimed to 
explore patients’ knowledge and attitudes towards antibiotic resistance and 
aspects of it. Examining these issues, could guide the development and/or 
refinement of interventions which target antibiotic use, by including appropriate 
and effective messages about antibiotic resistance. 
This chapter presents Study 2 which was published as an article entitled 
“Exploring patients’ understanding of antibiotic resistance and how this may 
influence attitudes towards antibiotic use for acute respiratory infections: a 
qualitative study in Australian general practice”. 
Work arising from this chapter was presented in oral form at the Gold Coast 
Research Week November 14, 2018 and was also presented at the Higher 
Degree of Research Conference October 16, 2018 at Bond University, Gold 
Coast (and awarded second place for best presentations). 
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Abstract 
Objectives— To explore patients’ or parents of child patients’ understanding of 
antibiotic resistance and aspects of resistance such as resistance reversibility 
and its spread among those in close proximity, along with how this may influence 
attitudes towards antibiotic use for acute respiratory infections (ARIs). 
Design— Qualitative semi-structured interview study using convenience 
sampling and thematic analysis by two researchers independently. 
Setting— General practices in Gold Coast, Australia. 
Participants— 32 patients or parents of child patients presenting to general 
practice with an ARI. 
Results— Five themes emerged: 1) antibiotic use is seen as the main cause of 
antibiotic resistance, but what it is that becomes resistant is poorly understood; 
2) resistance is perceived as a future ‘big problem’ for the community, with little 
appreciation of the individual impact of, or contribution to it; 3) poor awareness 
that resistance can spread between family members but concern that it can; 4) 
low awareness that resistance can decay with time and variable impact of this 
knowledge on attitudes towards future antibiotic use; and 5) antibiotics are 
perceived as sometimes necessary, with some awareness and consideration of 
their harms.  
Conclusions— Patients’ or parents of child patients’ understanding of antibiotic 
resistance and aspects of it was poor. Targeting misunderstandings about 
resistance in public health messages and clinical consultations should be 
considered as part of a strategy to improve knowledge about it, which may 
encourage more consideration about antibiotic use for illnesses such as ARIs. 
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Background 
Antibiotics, which have been critically important for treating infections since their 
discovery in the 1940s, are accelerating towards weakened effectiveness due to 
increase in antibiotic resistance (1). Antibiotic resistance, which occurs when 
bacteria change in response to the use of antibiotics and resist the effects of 
antibiotics, is largely driven by community antibiotic use (2-4). Antibiotics are 
prescribed more in primary care than other health sectors, and often for acute 
respiratory infections (ARIs), which comprise approximately 10% of primary care 
consultations (5). Because of high prescribing rates, particularly for common 
conditions where antibiotics provide little benefit such as sore throat (6), acute 
otitis media (AOM) (7), and bronchitis (8), primary care is targeted for reducing 
antibiotic prescribing. 
Understanding patients’ beliefs about antibiotics and reasons for using and not 
using them can help inform interventions and public campaigns that aim to 
encourage appropriate antibiotic use (9). Research has revealed that patients 
overestimate the benefits of antibiotics for ARIs (10), and their expectations can 
influence antibiotic prescribing (11). 
Research that has explored the public’s understanding of antibiotic resistance, 
consequences of it, and whether patients consider the threat of resistance when 
deciding, ideally in conjunction with their clinician, whether to use antibiotics is 
scarce (9,12). There are also aspects of antibiotic resistance that might affect 
perceptions about antibiotic use, but patients’ understanding of and views about 
these have not been investigated. This includes that antibiotic use increases 
resistance in the period following use, but this resistance decays with time (4), 
and that resistance can be transmitted between people in close proximity such 
as family and household members (13). How knowledge of this might influence 
patients’ beliefs about antibiotic use for minor self-limiting illnesses such as ARIs 
is unknown. Such information is needed to ensure that clinical consultations and 
public health campaigns about antibiotic use cover all the appropriate and 
relevant key messages. 
This study aimed to explore, in a sample of patients, or parents of child patients, 
presenting to a general practitioner (GP) directly after the decision-making point 
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in a clinical encounter for ARI, their understanding of: 1) antibiotic resistance in 
general; and 2) aspects of antibiotic resistance, including resistance decay and 
spread among people in close proximity, and how attitudes towards antibiotic use 
may be influenced by this understanding. 
Methods 
Design 
This was a qualitative study which used semi-structured interviews to explore 
participants’ understanding of antibiotic resistance and implications for decisions about 
antibiotic use.  
Participants and setting 
Recruitment and the interviews occurred in general practices in southeast Queensland, 
Australia that had been recruited as part of an ongoing cluster randomised trial (14). The 
trial intervention that was provided to the general practices was three patient decision aids 
(for acute otitis media [AOM], acute sore throat, and acute bronchitis) and a 15-minute 
video that demonstrated shared decision making. Practices randomised to the control 
group did not receive any active intervention.  
Recruitment of participants for this study occurred between September 2016 and June 
2017 from both the intervention and control practices. Practice managers’ approvals were 
obtained through email communication and recruitment days were organised according 
to each practice’s preference. Patients were eligible to participate if they met these 
criteria. The first was that they were an adult (or parent of a sick child) 18 years or older 
consulting a consenting GP with one of three ARIs (AOM, acute sore throat, acute 
bronchitis) for the first time for that illness episode. We recruited adults and children as 
both experience ARIs and with a few exceptions, the benefits and harms of antibiotics for 
ARIs, along with the risk and consequences of antibiotic resistance, are similar for both 
groups. Other criteria were that participants could understand and read English and 
provide written informed consent.  
Patient and public involvement 
No patients or members of the public were involved in the design of this study. However, 
they were involved in the development of the decision aids used by GPs in some of the 
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recruited general practices. Patients were involved in this study as participants. The 
results of this study were disseminated to interested study participants by email. 
Procedure 
The interviews were conducted by one author (MB), using an interview topic guide 
(summarised in Box). The topic guide was developed based on a systematic review of 
relevant literature (12), and findings from a cross-sectional study of Australian parents’ 
experiences of ARI management and antibiotic use in primary care (10). The questions 
were piloted with two eligible participants who were not recruited into the study, and 
minor rephrasing of some questions occurred after piloting.  
Some practices organised a room for the interviews, whereas at other practices, the 
interviews occurred in a private area of the waiting room. The recruitment process 
differed according to each practice’s preference. At some practices, the interviewer 
(assisted by practice staff) approached only patients who were waiting to see the GPs who 
were participating. At other practices, the interviewer approached all waiting patients and 
asked if they were waiting to see one of the participating GPs (GP names were listed and 
shown to patients). If so, recruitment proceeded. Patient eligibility was determined by 
asking the patients if they were suffering from one of the following symptoms (sore 
throat, cough, ear pain), with the diagnosis confirmed afterwards by the treating GP. 
Potential participants were provided with a verbal explanation of the study and a written 
study information sheet. After confirming eligibility and obtaining written consent, each 
participant was interviewed for an average of approximately 15 minutes directly after 
leaving the consultation room. Patients were interviewed directly after the consultation 
because this is: i) for most, the time of decision making about whether to take antibiotics, 
ii) important for reducing recall bias, and iii) enabled face-to-face interviews to occur. 
Interviews were audio-recorded, with participants’ consent, and transcribed verbatim 
afterwards. The interview recording was deleted if a patient was diagnosed by their GP 
as having an illness other than an ARI. This occurred for one recording as the patient had 
a cough from a chronic illness. 
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Box. Summary of topic guide for interviews 
Data analysis 
After 26 participants had been interviewed, a preliminary thematic analysis was 
undertaken. It was decided that data saturation had not occurred, and recruitment 
of participants continued until data saturation was obtained at 32 participants. 
This was defined as when no new ideas or constructs emerged from two 
consecutive interviews.15 Two authors (MB and EG) then independently used 
the process for thematic analysis outlined by Braun and Clark.16 After 
familiarising themselves with the interview transcripts, they generated 
overarching themes and subthemes. This was a data-driven process that was 
partially inductive in nature. The authors compared and discussed their themes 
and analyses and with the input of an additional researcher (TH), came to 
consensus. The themes and illustrative quotes were then agreed to by all authors.  
Results 
Participant characteristics 
We approached 208 patients in five general practices: 41 met the inclusion 
criterion of having an ARI, and of these, 32 (18 adult patients and 14 parents of 
sick children) consented to participate. The most common reason given for 
declining participation was insufficient time to be interviewed. Participants’ mean 
age was 38 years (range 18-74), the majority were female (n= 25, 78%), and half 
(n= 16, 50%) were consulting for an episode of acute bronchitis (Table 4).  
 
- ‘Usual’ approaches of expecting and/or using antibiotics for managing ARIs, 
including beliefs about necessity of antibiotics, their benefits and harms, and 
other influences on decision-making about antibiotic use 
- Understanding of the meaning of ‘antibiotic resistance’, its cause/s, and 
implications of it. [If the participant did not know what resistance was, the interviewer 
provided a brief explanation before proceeding to next questions] 
- Awareness that antibiotic resistance can spread between those in close proximity 
(such as family and household members) and if unaware, reactions to being told 
that it can  
- Awareness that antibiotic resistance can decay over time and if unaware, 
reactions to being told that it can 
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Table 4. Participant characteristics 
Participant 
ID 
Participant 
age (years)  
Gender  Presenting condition If child, age 
(years) 
P01 18 Female Sore throat  
P02 73 Male Acute Bronchitis  
P03 34 Female Acute otitis media (AOM) 1 
P04 47 Female Sore throat  
P05 37 Female Sore throat 1.3 
P06 34 Female Unspecified ARI 11 
P07 38 Female Acute Bronchitis  
P08 28 Female Acute Bronchitis  
P09 32 Female Acute Bronchitis 2 
P10 22 Male Acute Bronchitis  
P11 27 Female Sore throat  
P12 64 Male Acute Bronchitis  
P13 52 Male Acute Bronchitis 3 
P14 39 Male Acute Bronchitis 2 
P15 36 Female AOM 6 
P16 43 Female Acute Bronchitis 3 
P17 18 Female Sore throat  
P18 43 Female Sore throat  
P19 70 Female Acute Bronchitis  
P20 45 Female Sore throat  
P21 34 Male Acute Bronchitis  
P22 30 Female AOM 4 
P23 74 Female Acute Bronchitis  
P24 25 Female Acute Bronchitis 1.3 
P25 24 Female Sore throat  
P26 18 Female Acute Bronchitis  
P27 36 Female Unspecified ARI 3 
P28 21 Male Unspecified ARI  
P29 50 Female Unspecified ARI  
P30 34 Female Acute Bronchitis 2 
P31 38 Female Acute Bronchitis 4.5 
P32 35 Female AOM 1.8 
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Themes 
Five themes emerged, and these are presented below and supported by 
illustrative quotes.  
Theme 1. Antibiotic use is seen as the main cause of antibiotic resistance, but 
what it is that becomes resistant is poorly understood.  
Many participants thought that antibiotic overuse or misuse in people drives 
antibiotic resistance - “Sometimes people think they need antibiotics. That’s 
where they can lead to resistance because they have them too much” (P03); with 
a few mentioning other reasons such as antibiotic use in animals; “Through our 
food, that sort of thing, it does seem to be a concern now. Like, animals getting 
fed antibiotics” (P12); or not using the full antibiotic course “But if you use them 
… you don’t take the full dose, obviously like in that you’ve got your certain bugs 
coming out.” (P25). 
Nearly all participants thought that antibiotic resistance is when the body 
becomes resistant to antibiotics: 
“Antibiotic resistance, your body is resistant to it and maybe you’ve used too 
much of it… antibiotics” (P16) 
“Antibiotic resistance is possibly your body, rejecting the benefits of the 
antibiotics … it’s almost like the body gets used to the antibiotic” (P10)  
“If you take antibiotics too regularly, your body stops, reacting to them, or they 
stop having an impact” (P04)  
Some participants still had misperceptions after the interviewer provided a simple 
explanation of what antibiotic resistance is (“Antibiotic resistance happens when 
bacteria change to protect themselves from an antibiotic. They are then no longer 
killed by that antibiotic”): 
“Oh, yeah, see I’ve never had that sort of problem. I’ve never heard it. 
Whenever I’ve taken it, maybe I wasn’t sick enough to sort of resist it. It’s 
always worked. And for the time that I had to take more than once, a repeat, 
you know.” (P23) 
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Theme 2. Resistance is perceived as a future ‘big problem’ for the community, 
with little appreciation of the individual impact of, or contribution to it 
Most participants perceived antibiotic resistance as a community problem caused 
by others who misuse antibiotics:  
“… if people are over using it. Yeah, especially with their children when they’re 
so young. If they’re regularly on antibiotics, yeah….” (P06) 
“I imagine there would be some pockets of the community that it [antibiotic 
resistance] might be an issue for.” (P04) 
“I think it’s a big problem. People like to get antibiotics and just solve things 
instantly. Like people don’t like to wait and see what happens, they like to get 
something – even if they think it’s going to work or not, they just – something 
to make it better.” (P15) 
Most participants described resistance as a problem that will not impact them 
individually - “I don’t think it’s a big issue for me” (P09); “I think I’ll get through my 
life without it impacting on it” (P21). A few participants described their worry about 
antibiotic resistance, although by many it was viewed as a future or a hypothetical 
concern:  
“Oh, huge, I don’t want that to happen… Um, well, if she got sick and 
constantly needed antibiotics… you know, then obviously in - as she gets 
older, they’d stop working as much as you wouldn’t be able to treat infections 
as much and I don’t want that to happen” (P03) 
“… it could become a big problem if the so-called superbugs, um, come out 
and about later on, yeah.” (P09) 
 “It still concerns me, um, because someone as young as my two-year-old son 
– I guess in an older person, it’s perhaps not as concerning because over the 
course of a life time... but I think the message is out there that maybe you need 
to think twice before (using antibiotics)” (P09) 
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Theme 3. Poor awareness that resistance can spread between family members 
but concern that it can  
Most participants did not know that antibiotic resistance can spread between 
people who are in close proximity, such as family members - “No, I didn’t even 
know it could spread” (P24). Some thought it would be possible:  
“Um, I’ve never really thought about it before. My initial answer would be no, 
but I guess like if – yeah I guess if one of the children had a bug that was 
tougher, and they gave that to the other child, then, yeah, I guess, yeah, I 
guess it would be” (P32). 
When participants were told by the interviewer that it can, the most common 
reaction was concern “concerned. Yeah, it’s not a good thing” (P14) and shock 
“Oh, shocked. No, I never knew that.” (P01), with some insight into the 
significance of the problem “So by one person using antibiotics can create 
problems for the whole family… Yeah. Well, that’s, um, not real good, is it?” (P19) 
Some participants suggested strategies to minimise the spread of resistance 
such as decreasing antibiotic use “…. so not using them too much” (P03) or with 
hand hygiene (“hand sanitiser” (P21), “wash hands” (P07)).  
Theme 4. Low awareness that resistance can decay with time and variable impact 
of this knowledge on attitudes towards future antibiotic use 
Most participants did not know that antibiotic resistance could decay over time:  
“Oh, I’ve got no idea, I thought it just – that it stayed for a lifetime if you were 
resistant to it.” (P24) 
 “Oh, a long time. You’d have to - it’d take a lot of different ways to treat it” 
(P03) 
 “I imagine not, because once it’s in your system, it remains there” (P09) 
There was wide variation on estimation of the time to decay, ranging from days 
to decades: 
“It wouldn’t be; you wouldn’t think within a couple of days… but I’m not saying 
12 months or anything like that” (P19) 
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 “Oh, probably ten years or something, crazy” (P15) 
After explanation from the interviewer that antibiotic resistance does decay, some 
participants were more hopeful about the problem of antibiotic resistance: 
“…it’s promising to know that there is a chance … given enough time, then 
they [Antibiotics] could work again” (P21) 
“Yeah, well that’s good that it could be then reversible” (P32) 
“It makes me think that you could possibly go back to using those antibiotics if 
you had the similar problem maybe 18 months down the track” (P10) 
It was assumed by some that science will come up with solutions to manage 
antibiotic resistance in the future: 
“I don’t think it will go away, but I think maybe people are coming up with 
different solutions to fight it rather than antibiotics or different ways of switching 
off you know our body’s responses and things like that.” (P15) 
“It will be interesting over the next 10-15 years. I think that probably there’ll be 
some really good break throughs in -- in the engineering and the science 
behind antibiotics…” (P21) 
The impact of knowing about resistance decay on attitude towards antibiotic use 
was variable. Some participants indicated no change (“No different than I said 
before.  If it means it’s [antibiotics] going to save my life and help me in my health, 
it wouldn’t make any difference at all. (P23)), whereas others expressed that 
knowing this made them more cautious:  
“That makes me really think about it – taking antibiotics only if you really need 
to” (P08) 
“Especially for the children it would a lot scarier that they wouldn’t be able to 
be treated … if they were sick and something. It’s quite frightening.” (P22) 
 Theme 5. Antibiotics are perceived as sometimes necessary, with some 
awareness and consideration of their harms  
Antibiotics were seen as beneficial by many participants (“only thing that helps” 
(P20)). The most commonly reported perceived benefits were decreased duration 
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of illness (“taking antibiotics would make me better quicker” (P11)) and decreased 
severity or progression of the infection (“to make sure it doesn’t go to any further 
stages of infection.” (P06)).  
Some participants believed in the need for antibiotics, despite being told by their 
GP that antibiotics would not help with viruses or provide better outcomes for 
them: 
“… the doctor said oh it’s a virus, I said well I’m going to be looking after my 
grandchildren, it’s school holidays, and I needed something to help me get 
over this. …and she said but they are not going to help you. I said well it’s my 
decision at the time to have them because I didn’t want my children to have 
what I had, you know. It was just a very bad virus I had, you know. But anyway, 
the antibiotics did work.” (P23) 
Some participants were reluctant to take antibiotics for minor self-limiting 
illnesses, such as ARIs, and preferred to reserve antibiotic use for severe 
infections - “I would be hesitant. So, yes, maybe each time my doctor gives me 
antibiotics, I would ask is that necessary?” (P07), with some concerned about not 
wanting to overuse antibiotics - “should be more carefully applied and perhaps 
conservatively used.” (P18). Others’ attitudes about antibiotic use were not 
influenced by illness severity - “…doesn’t really change my opinion of it… certain 
antibiotics really work” (P25). Some participants’ reasons for not using antibiotics 
were to “give the body the best fighting chance” (P15) and by “trying natural 
healing and staying healthy in the first place” (P13) 
The few participants who had personal experience of antibiotic resistance were 
particularly cautious about antibiotic use: 
“…because of my bronchitis… I have taken other medications that haven’t 
worked. The – the doctors then had to change it… to a different medication. 
Yeah. Because I become resistant to others so I’m very fussy about taking 
them.” (P20) 
There was great variability in participants’ awareness of the potential harms of 
antibiotics. Many participants named potential side-effects with commonly listed 
ones including “vomiting”, “nausea”, “thrush”, and “diarrhoea”. Some mentioned 
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“possible resistance” as one of their concerns, but responses conveyed 
misunderstanding of what antibiotic resistance actually is. Some participants 
were not aware that antibiotics had potential harms - “None that I’m aware of” 
(P21).  
The patient-clinician relationship was viewed as very important when decisions 
about the management of infections were being made. Trust in the clinicians’ 
recommendation for antibiotic use was mentioned by some - “as long as I can 
talk to my doctor and trust that the doctor is making the right decision” (P05)  
Some participants described a lack of information and discussion with their 
clinician “I don’t have enough information to probably correctly make that call.” 
(P18) and were unaware of the option to not treat with antibiotics (that is, that the 
illness would get better without them) “Um, well I guess when it’s infected there’s 
not really much other choice for that particular problem” (P32). 
Some expressed a desire for more information about antibiotic resistance:  
“Um, yeah, it would be good to know more about, um, how often you have to 
be taking them for resistance to build, whether individual, patient to patient” 
(P18).  
 “… interested in knowing more information about (antibiotic resistance)” (P15) 
Discussion 
This study has identified five major themes that related to people’s understanding 
of antibiotic resistance and aspects of resistance such as resistance reversibility 
and spread among those in close proximity such as family or household 
members. While many participants articulated the link between antibiotic use and 
resistance, there was confusion about the nature of antibiotic resistance, which 
was often attributed to a trait of the body rather than bacteria in the microbiome. 
Many saw antibiotic resistance as a potential problem, rather than one that exists 
already, and that it was a consequence of and problem for the others in the 
community rather than them as an individual. Few appreciated the potential for 
antibiotic resistant organisms to spread between those in close proximity, or that 
antibiotic resistance can decay.  
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Most participants reported the main benefit of antibiotic use was a decreased 
duration of illness. Some were aware of the potential for harm from antibiotics, 
including resistance. Some expressed reluctance to use antibiotics for minor self-
limiting infections because of concern about overuse or misuse, whereas for 
others, it was not because of the potential harms but because of a preference for 
allowing their body to fight the infection naturally.  
The poor understanding of the nature of antibiotic resistance has been found in 
previous studies in a general practice setting (17) and in non-healthcare settings 
(18-20). A recent survey of the UK general adult population showed that lack of 
antibiotic resistance awareness was strongly associated with self-reported 
likelihood of requesting antibiotics for an influenza-like infection (21).  It appeared 
that patients who had personal experience of antibiotic resistance were the most 
reluctant to use them again, preferring to reserve their use for serious illness. A 
survey of the general population in Germany found that people who knew of 
someone suffering from multidrug-resistant organisms, received more 
information by their clinician on antibiotic resistance and took less antibiotics for 
an infection (of any cause), compared with people who did not have any personal 
involvement (19).  
Our finding that the lack of individual ‘ownership’ of contribution to, or risk of, 
antibiotic resistance has previously been identified in a systematic review (12), 
which showed that the public do not believe they contribute to the development 
of antibiotic resistance. This is complemented by the finding that some 
participants believe that science will find a way to solve the resistance problem, 
which contradicts with messages about individuals needing to change their 
behaviour to minimise the problem.  
Many public health campaigns convey the message of antibiotic resistance and 
how it is promoted by inappropriate antibiotic use and misuse. The effect of some 
campaigns has been analysed and a decrease in antibiotic use was found (22, 
23). Some of our findings might be useful in guiding and refining the content of 
messages in public health campaigns and clinical consultations about antibiotic 
resistance. For example, the information that developing antibiotic resistance in 
one’s microbiome might also lead to resistance in people who are physically close 
to them, such as family members, could be an additional message in patient and 
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public educational strategies to encourage appropriate antibiotic use. Most 
participants were quite concerned upon learning about resistance spread and it 
prompted some to provide suggestions for how to minimise resistance 
development and its spread – suggesting that perhaps this is the information that 
could contribute to altering people’s attitudes and behaviour about antibiotic use 
for minor self-limiting illnesses. 
Future research into the optimal information about antibiotic use and resistance 
to include in public messages and clinical consultations is recommended. This 
includes the potential utility of information about resistance decay and its impact 
on antibiotic use. Knowing that resistance decays over time if antibiotics are not 
used promoted hope in some people that the problem of resistance was not 
irreversible and that efforts to conserve antibiotic effectiveness by not using 
unless essential are worthwhile. However, for others, knowing that resistance 
decay occurs over time, may thwart attempts to encourage responsible antibiotic 
use.  
At a clinical consultation level, better engagement with patients when antibiotics 
are being considered by providing a balanced discussion of antibiotic benefits 
and harms is encouraged. This conversation should include discussion that 
resistance is a potential harm of antibiotic use, and explanation of the possible 
consequences of it for the individual and the broader community.   
A limitation of our study is that the sample is not representative of the wider 
Australian population as participants were recruited from one city in Australia, 
only those presenting with an ARI were invited, and the majority of participants 
were female. For a small number of participants (9), there is the risk that their 
knowledge about antibiotic resistance was influenced by their GPs’ use of a 
patient decision aid - which included a very brief explanation of what resistance 
is, but not about the spread or decay of resistance. Although GPs who did not 
receive or use the aids may have mentioned resistance as part of the consultation 
regardless. Other limitations are that participants did not have the opportunity to 
provide feedback on the themes derived from the interviews and the short 
duration of the interviews—which could have affected the depth of the gathered 
information. Strengths of the study include the use of two researchers 
independently performing the thematic analysis and its contribution of new 
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findings to this field. We are not aware of other studies which have explored 
people’s knowledge about the potential for antibiotic resistant organisms to 
spread between those who are in close proximity or that antibiotic resistance 
decays over time. 
Conclusion 
This study found that patients’ understanding of many aspects of antibiotic 
resistance was poor including: what it is, individual contribution to its 
development, individual implications, its spread and decay. Incorporating 
messages that target misunderstandings into public health messages and clinical 
consultations may be an important strategy to encourage more appropriate use 
of antibiotics for illnesses such as ARIs. 
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Preamble 
The previous studies in (Chapters 3 and 4) discussed the importance of GPs and 
patients having a balanced discussion about antibiotic benefits and harms during 
consultations about ARIs. Including antibiotic resistance as one of the harms of 
using antibiotics in this discussion is a valuable way to improve patients’ 
understanding of antibiotic resistance and implications of antibiotic use. As part 
of the antibiotic use decision, clinicians may wish to consider the timeframe to 
resistance decay after antibiotic use. 
A previously published systematic review showed that antibiotic use is associated 
with increased isolation of resistance organisms up to 12-month after antibiotic 
exposure in primary care (1). However, as explained in Chapter 2, there is a need 
to update the evidence behind antibiotic resistance decay and to explore if the 
decay behaviour varies by antibiotic class or type of bacterium. 
 
This chapter consists of the paper titled “Resistance decay in individuals after 
antibiotic exposure in primary care: a systematic review and meta-analysis”, 
published in BMC Medicine. It examines the development and decay of bacterial 
resistance after antibiotic use in individuals from the community. 
 
Work arising from this chapter was also presented in oral form at the National 
Medicines Symposium 2018 in Canberra. Additionally, this work was presented 
as a poster at the Higher Degree of Research Conference 2016 at Bond 
University, Gold Coast, where it won “Best Poster Award-by judges”. 
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Abstract 
Background— Antibiotic resistance is an urgent global problem, but reversibility 
is poorly understood. We examined the development and decay of bacterial 
resistance in community patients after antibiotic use. 
Methods— This was a systematic review and meta-analysis. PubMed, EMBASE 
and CENTRAL (from inception to May 2017) were searched, with forward and 
backward citation searches of the identified studies. We contacted authors whose 
data were unclear, and of abstract-only reports, for further information. We 
considered controlled or times-series studies of patients in the community who 
were given antibiotics and where the subsequent prevalence of resistant bacteria 
was measured. Two authors extracted risk of bias and data. The meta-analysis 
used a fixed-effects model. 
Results— Of 24,492 articles screened, five controlled and 20 time-series studies 
(total 16,353 children and 1461 adults) were eligible. 
Resistance in Streptococcus pneumoniae initially increased fourfold after 
penicillin-class antibiotic exposure (odds ratio (OR) 4.2, 95% confidence interval 
(CI) 3.5–5.4), but this fell after one month (OR 1.7, 95% CI 1.3–2.1). After 
cephalosporin-class antibiotics, resistance increased (OR 2.2, 95%CI 1.7–2.9); 
and fell to (OR 1.6, 95% CI 1.2–2.3) at one month. After macrolide-class 
antibiotics, resistance increased (OR 3.8, 95% CI 1.9–7.6) and persisted for one 
month (OR 5.2, 95% CI 2.6–10.3) and three months (OR 8.1, 95% CI 4.6–14.2, 
from controlled studies and OR 2.3, 95% CI 0.6–9.4, from time-series studies). 
Resistance in Haemophilus influenzae after penicillins was not significantly 
increased (OR 1.3, 95% CI 0.9–1.9) initially but was at one month (OR 3.4, 95% 
CI 1.5–7.6), falling after three months (OR 1.0, 95% CI 0.5–2.2). Data were 
sparse for cephalosporins and macrolides. 
Resistance in Enterobacter increased post-exposure (OR 3.2, 95% CI 0.9–10.8, 
from controlled studies and OR 7.1, 95% CI 4.2–12, from time-series studies), 
but was lower after one month (OR 1.8, 95% CI 0.9–3.6). 
Conclusions— Resistance generally increased soon after antibiotic use. For 
some antibiotic classes and bacteria, it partially diminished after one and three 
months, but longer-term data are lacking and urgently needed. 
Review registration—PROSPERO CRD42015025499. 
Chapter 5: Evidence about resistance development and decay 
[89] 
Background 
The discovery of penicillin in the mid-20th century heralded the antibiotic era (2, 
3), and contributed significantly to a decrease in the rates of morbidity and 
mortality that had been caused by previously life-threatening infections (4, 5) 
However, antibiotic resistance emerged shortly afterwards (6). This drove the 
discovery of new antibiotics (5). However, the development of new antibiotics is 
no longer keeping up with resistance (7) and we now face the threat of a post-
antibiotic era (8-10). 
Antibiotic resistance is generated by its use (8). One area of interest is the high 
use of antibiotics in primary care, particularly for the treatment of acute respiratory 
infections, for which there is very little or no benefit (11-15) Yet many clinicians in 
primary care persist, believing that resistance is not their problem (16-18).     
Systematic reviews suggest that prescribing antibiotics in primary care initially 
increases the prevalence of resistant bacteria in patients—more so in countries 
with higher prescribing rates (19) – but that they became less detectable in the 
microbiome after 12 months (1). The return of the microbiome to antibiotic 
susceptibility is critical in encouraging a reduction of antibiotic use, which is being 
actively pursued in the primary-care community internationally to minimise 
antibiotic resistance. What remains unknown is the time this takes, and how it 
varies by antibiotic class and bacterium. 
This information is important for informing public health messages, antibiotic 
resistance campaigns and clinician training. This systematic review aimed to 
identify and synthesise prospective studies that have examined the occurrence 
of bacterial resistance in community-based patients who were exposed to 
antibiotics, and to explore whether resistance decay varies by antibiotic class and 
bacterium. 
Methods 
We initially planned simply to update a previous systematic review that had 
addressed resistance decay (1). However, we were unable to replicate the search 
(since there were discrepancies in the numbers of studies found and differences 
in the eligible and included studies identified) and also realised that the time 
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points were poorly discriminated, especially those from retrospective studies. The 
design of retrospective studies means that: 1) they can report only the time 
interval between antibiotic exposure and the isolation of resistant isolates at the 
end of the study, with no data in between; 2) details of the exposure antibiotic, 
such as type and dose, are often unknown and 3) there is often a selection bias 
towards patients with treatment failure. Accordingly, we undertook this review de 
novo. 
This research was reported in line with the Preferred Reporting Items for 
Systematic Reviews and Meta Analyses (PRISMA) (20). 
Eligible study designs 
Eligible studies compared antibiotic-exposed participants to controls (including 
randomised controlled trials or RCTs), or involved prospective repeat measure 
cohorts that reported the prevalence of resistant bacteria among patients, 
isolates or specimens (percentage of resistant isolates from each swab) over 
time. Retrospective studies were also identified as part of the same search 
process but will be reported separately. Case reports were ineligible. 
Eligible participants 
We included studies of patients (or isolates from them), of any sex or age, 
symptomatic or asymptomatic, who were treated in the community or had 
community-acquired infections. Studies that included patients with hospital-
associated infections, device-related infections and persistent infections were 
ineligible (Supplementary Material 4). 
Eligible types of antibiotic exposure 
We included any study in which participants in the index group were exposed to 
a short antibiotic course (≤2 weeks), of any antibiotic class. 
Eligible comparison 
Groups of participants who either did not use antibiotics (controls) or used them 
at different times were eligible as comparators. 
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Outcomes 
The primary outcome was the isolation of resistant bacteria at a pre-specified 
time point. Studies that did not report the duration between the last known 
antibiotic exposure and isolation of resistant bacteria, or did not report the before 
and after prevalence of resistant and susceptible isolates in studies comparing 
two antibiotic exposures, were excluded. 
Search and information sources 
We searched PubMed, EMBASE and the Cochrane Central Register of 
Controlled Trials (CENTRAL) from inception until the first week of May 2017, 
using medical subject headings (MeSH) and keywords: ‘Drug Resistance’ AND 
‘Anti-Bacterial Agents’ AND ‘Primary Health Care’ AND ‘Patients’ with a detailed 
search strategy (Supplementary Material 5). Forward and backward citation 
searches identified additional relevant studies. We contacted authors whose data 
were unclear, and of abstract-only reports, for further information. 
Study selection 
Two researchers (MB and JR) independently screened the titles and abstracts of 
search results using Endnote (version X8) and the Rayyan website for systematic 
reviews (21), and then the full texts of remaining studies for inclusion. A third 
reviewer (CDM or TH) resolved any disagreements. 
Data extraction 
Two researchers (MB and AS) used a pre-specified and pre-piloted form to 
independently extract data on: study design, study duration, symptomatic or 
asymptomatic patients, age, recruitment location, total number of reported 
patients and isolates, methods of sampling, and collection of antibiotic exposure 
data and analysis. Disagreements were resolved by consensus or third author 
(CDM or TH). 
Assessment of risk of bias 
Two researchers (MB and AS) independently evaluated the risk of bias, using the 
Cochrane Risk of Bias tool (22) for RCTs, or, for other study designs, items 
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adapted from the Risk of Bias in Non-Randomised Studies, Interventions 
(ROBINS-I) tool (23) (Box 2). 
Box 2. Items adopted from ROBINS-I tool for the included cohort studies 
 
Data analysis 
We derived the odds of identifying resistance at different time points. Some 
studies limited the denominator to participants carrying bacteria and others to 
total participants (those carrying bacteria or not). We included only data from 
participants carrying bacteria, which enabled comparisons, as we are interested 
in the burden of resistance on the community. We extracted incident cohort 
counts, where reported. If they were not, we manually calculated them from odds 
ratios (ORs). When resistance data were reported for more than one antibiotic, 
we analysed only resistance to the same antibiotic to which participants were 
exposed (to avoid duplication), and co-resistance data were extracted and 
reported in separate tables. Some studies reported resistance as ‘intermediate’ 
and ‘high’: we collapsed these into ‘resistant’.  
We use the term ‘prospective repeated measures cohort studies’ to describe 
those that were randomised trials by design but in which the data were extracted 
from each arm of the trial separately without the benefit of randomisation. These 
were analysed with the cohort studies. The main study designs are detailed in 
Table 5. 
Resistance prevalence data can be compared at different time points in two ways, 
according to study design: a separate control group (methodologically more 
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robust) or studies reporting before and after antibiotic exposure. We meta-
analysed the two methods separately, but present them adjacently. 
To facilitate comparisons, we collapsed the reported time periods after antibiotic 
exposure to pre-specified ranges: pre-exposure and from end of treatment (i.e. 
time 0): 0 to ≤1 week, >1 week to ≤1 month and >1 to ≤3 months. When the same 
study reported multiple resistance data that fell in the same pre-specified ranges, 
we chose the latest time point provided. We undertook the meta-analysis using 
RevMan Version 5.3 (24), pooling Peto ORs from the end of treatment with a 
fixed-effects model to correct better for zero cell counts (22). We assessed 
statistical heterogeneity among studies with a χ2 test (using P≤ 0.05 for significant 
heterogeneity) and I2. Subgroup analyses were pre-specified by the time since 
last antibiotic exposure. We were not able to test for statistical differences 
between different times using either a statistical test for trend or a χ2 test for 
heterogeneity of the different time subgroups, as some studies provided data for 
different time points, but not all. 
Protocol and registration 
The review protocol was registered on the PROSPERO database 
(CRD42015025499) at 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD420150254
99 . Ethics approval was not required. A modification of the protocol was to clarify 
that studies that had reported resistant bacteria at the isolate level were also 
eligible (Appendix 4 Systematic review protocol). 
Results 
Study selection  
Our search found 24,117 citations, supplemented by 5878 citations identified 
from forward and backward searches of references cited in included studies, 
which, after removing duplicates, left 24,492. Screening by title and abstract 
excluded 23,934, leaving 558 for which the full text was screened. After excluding 
379 (Supplementary Material 6 gives detailed reasons for exclusion), 179 eligible 
articles remained, of which 25 studies (in 26 articles) assessed the isolation of 
resistant bacteria prospectively. These were included in this review (Fig. 5). 
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Fig. 5. Study flow chart 
Study characteristics 
Of the included studies, five were RCTs (25-29) and 20 were prospective cohort 
studies (30-50). We report the study design here in relation to the outcome of 
resistance, although some studies were RCTs for the outcome of efficacy. Table 
5 shows study characteristics. All but three (26, 29, 39) were conducted in one of 
the Organisation for Economic Co-operation and Development countries (OECD 
countries): 
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- 16 investigated children (total of 16,353) (26, 29-34, 36-41, 44, 45, 48-50), 
and 8 studied adults (total of 1,461) (25, 27, 28, 35, 42, 43, 46, 47) 
- 14 investigated symptomatic patients, (12 with respiratory infections (28, 30-
34, 36-38, 48-50); 1 with urinary infections (42); 1 with acute febrile illness 
(47)) 
- 6 involved asymptomatic participants (25, 27, 29, 35, 43, 46) 
- 5 studies included both (26, 39, 41, 44, 45).  
Twelve compared antibiotic exposure against a control or placebo (25-31, 39, 
41, 43, 45, 47), and 13 were antibiotic comparison studies (32-38, 42, 44, 46, 
48-50). Antibiotics from the following classes were studied: penicillins (14) (28, 
30-38, 41, 48-50); macrolides (12) (25-27, 29, 37, 39, 41, 44, 46, 49, 50); 
cephalosporin (8) (31-33, 36-38, 49, 50); sulphonamides and trimethoprim (2) 
(42, 45); quinolones (1) (46); lincomycin (1) (43), ketolides (1) (35) and one study 
included any antibiotic (47).  
Risk of bias in studies and heterogeneity assessment  
The risk of bias was assessed based on the study design for the outcome of 
resistance, not the original study design for the outcome of efficacy. The overall 
risk of bias was low, although bias due to selective reporting was uncertain for 
most RCTs because resistance was often not nominated as an outcome and 
there was an unclear risk of bias for the outcome measurement in the cohort 
studies (Fig. 6). We were not able to test for publication bias for the examined 
outcomes because of the very low number of studies in each funnel plot 
(Supplementary Material 7). There was considerable variation in the 
heterogeneity between studies, particularly for the cohort studies (Figs. 7, 8 and 
9). 
Table 5. Characteristics of included
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Resistance in respiratory tract bacteria 
Bacteria were isolated from the respiratory tract in 19 studies and from the 
conjunctiva in one study. 
Streptococcus pneumoniae and penicillin exposure 
Penicillin-resistant Streptococcus pneumoniae were studied in only one 
controlled study (with 35 participants). Before exposure to penicillin, resistance 
was not significantly different between the group of patients subsequently 
exposed and those not exposed [OR 2.8, 95% confidence interval (CI) 0.5–15.3]. 
After exposure, the OR of resistance in those exposed was 9.4 (95% CI 0.6–
149.3). After 3 months, there was no longer a significant difference in resistance 
(OR 0.4, CI 0.02–9.8; Fig. 7). 
There were more data from prospective repeated measures cohort studies that 
compared resistance rates before antibiotic exposure (baseline data) and after 
penicillin exposure after 1 week (0 to 7 days; 6 studies, 1060 participants and 8 
antibiotic exposure groups) and after 1 month (>1 week to ≤1 month; 4 studies, 
772 participants and 5 antibiotic exposure groups). After 1 week, resistance had 
increased significantly (OR 4.2, 95% CI 3.3–5.4). Thereafter, resistance had 
reduced after 1 month (OR 1.7, 95% CI 1.3–2.1; Fig. 7). 
One RCT (28) investigated reported resistance in isolates (rather than 
individuals) after exposure to amoxicillin and its data are analysed separately. It 
found that the changes in resistance following amoxicillin exposure were short-
lived, returning to normal by 1 month after the end of treatment (Fig. 7). 
S. pneumoniae and cephalosporin exposure
There were no RCTs. Four cohort studies (519 participants and 8 different 
antibiotic exposure groups) reported that resistance had increased at 1 week after 
exposure (OR 2.2, 95% CI 1.7–2.9), persisting after 1 month (OR 1.6, 95% CI 
1.2–2.3; Fig. 7). 
S. pneumoniae and macrolide exposure
There were three controlled studies. After a month, one small study reported the 
OR of resistance was 6.3 (95% CI 0.4–103.2). In three studies (437 participants), 
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it remained high (OR 8.1, 95% CI 4.6–14.2) at 3 months.  An RCT (27) of isolates 
found that a single course of macrolide-class antibiotics caused increased 
resistance in the first week immediately after macrolide use, and resistance 
remained significantly higher than the placebo group for more than 3 months 
(data not shown).  
Three cohort studies (101 participants and 3 different antibiotics) reported 
increased resistance at 1 week (OR 3.8, 95% CI 1.9–7.6). Three studies (147 
participants and 3 different antibiotics) found that after 1 month, resistance was 
increased (OR 5.2, 95% CI 2.6–10.3). There were 3-month data from only one 
study (OR 2.3, 95% CI 0.6–9.4; Fig. 7). 
Haemophilus influenzae and penicillin exposure 
Two RCTs (117 participants) found comparable resistance between groups 
before exposure to penicillin (OR 0.8, 95% CI 0.4–1.7). One week after exposure, 
resistance had increased non-significantly in one RCT (with only 4 participants; 
OR 7.4, 95% CI 0.2–374). Increased resistance persisted for 1 month in another 
RCT (102 participants; OR 3.4, 95% CI 1.5–7.6). At 3 months, in this study, 
resistance had returned to normal (OR 1.0, 95% CI 0.5–2.2). 
In four cohort studies (356 participants and 5 different antibiotic exposure 
groups), resistance was not increased at 1 week (OR 1.3, 95% CI 0.9–1.9). In 
two of the four cohort studies (183 participants and 3 different antibiotic exposure 
groups), it remained not increased at 1 month (OR 1.3, 95% CI 0.7–2.2; Fig. 8). 
H. influenzae and cephalosporin exposure 
There were no RCTs. Three cohort studies (229 participants and 3 different 
antibiotic exposure groups) found resistance had not increased at 1 week (OR 
1.2, 95% CI 0.7–1.9) or at 1 month (255 participants; OR 1.3, 95% CI 0.9–2; Fig. 
8). 
H. influenzae and macrolide exposure 
One RCT (175 participants) reported data at two time points. Before exposure, 
resistance was not significantly different between groups (0.6, 95% CI 0.3–1.3) 
and directly after macrolide exposure, resistance had increased in the exposed 
group (OR 2.5, 95% CI 0.8–8.2). One cohort study also reported two time points. 
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Resistance had increased after exposure at 1 month (OR 2.0, 95% CI 0.3–12.9) 
and it had decreased by 3 months (OR 0.5, 95% CI 0.1–3.1; Fig. 8). 
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Fig. 7. Pooled ORs for resistance in respiratory tract bacteria (Streptococcus pneumoniae) and antibiotic exposure 
by class. Studies grouped by time from the end of antibiotic exposure 
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Fig. 8. Pooled ORs for resistance in respiratory tract bacteria (Haemophilus influenzae) and antibiotic exposure by class. Studies 
grouped by time from the end of antibiotic exposure 
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Resistance in other respiratory bacteria 
The heterogeneity in five studies of resistance to non-groupable streptococci, 
Moraxella catarrhalis, Staphylococcus aureus, beta-lactamase producers and 
Streptococcus mitis, exposed to different antibiotic classes (penicillins, 
cephalosporins, macrolides, ketolides and quinolones), precluded meta-analysis. 
However, Supplementary Material 8 shows a forest plot for the studies. 
Resistance in Gram-negative gastrointestinal tract bacteria to several antibiotics 
Trimethoprim and β-lactams exposure: In one RCT (with 64 participants), before 
antibiotic exposure, the OR of isolating resistance was not significantly different at 0.8 
(95% CI 0.3–2.3). Two controlled studies (with 179 participants) compared antibiotic 
exposure against a group with no exposure. It found that 1 week after antibiotic 
exposure, the OR of isolating resistant Gram-negative bacteria was 3.2 (95% CI 0.9–
10.8; Fig. 9). 
Trimethoprim and trimethoprim-sulfamethoxazole exposure: From two cohort studies 
(129 participants and 3 different antibiotic exposure groups) the OR of isolating 
antibiotic-resistant Enterobacteria was 7.1 (95% CI 4.2–12) at 1 week. In one study 
(with 93 participants and 2 different antibiotic exposures), the OR was 1.8 (95% CI 
0.9–3.6) at 1 month (Fig. 9). 
One RCT (43) investigated the consequences of a 1-week course of clindamycin on 
Bacteroides species using isolates rather than participants as the unit of analysis. It 
reported that the numbers of isolates returned to pre-treatment levels after 3 weeks in 
the exposed group. However, the isolates demonstrated qualitative changes to their 
diversity, and resistance genes remained 2 years later (data not shown). 
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Fig. 9. Pooled ORs for resistance in Gastrointestinal tract bacteria and antibiotic exposure by 
class. Studies grouped by time from the end of antibiotic exposure 
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Co-resistance in participants in included studies 
Nine of the included studies reported selection for resistance to a different 
antibiotic than the exposure antibiotic (co-resistance). In respiratory isolates, 3 
months after azithromycin exposure, the OR of isolating clindamycin-resistant S. 
pneumoniae (OR 4, 95% CI 1.6–10.1) and erythromycin-resistant S. pneumoniae 
(OR 2.1, 95% CI 1.1–3.9) was significantly higher between exposed and 
unexposed groups. In gastrointestinal tract Enterobacteria, there was a 
significant increase in the odds of isolating trimethoprim-resistant bacteria 
immediately after exposure to trimethoprim/sulfamethoxazole (OR 4.5, 95% CI 
1.8–11.7; Supplementary Material 9). 
Discussion 
Our systematic review found that antibiotic resistance in either the respiratory or 
gastrointestinal tracts of people in the community increased immediately after 
treatment with any of the antibiotics studied. This generally decayed over the next 
month, particularly in S. pneumoniae isolates treated with penicillins. The effect 
of cephalosporins on resistance was less pronounced at 1 week but persisted for 
at least for a month. After macrolide exposure, resistance persisted for at least 3 
months. The paucity of controlled studies means there is some uncertainty 
around the estimates of the rate of decay of resistance in the macrolides. 
There was no significant difference in isolation of resistant H. influenzae following 
penicillin or cephalosporin exposure. For macrolides, there were not enough data 
to examine this. For Gram-negative bacteria in the gastrointestinal tract, resistant 
bacteria were detectible 1 month after antibiotic exposure, decaying from 
immediately after exposure. 
Antibiotic resistance may well predate the human exploitation of antibiotics (51). 
Our data show that baseline antibiotic resistance increases after antibiotic use. 
The mechanism by which this happens includes selection of bacteria with the pre-
existing gene and the acquisition of the resistance gene from other organisms in 
the microbiome. Similar mechanisms may be operating in the reversal of 
resistance when antibiotics disappear from the host environment. 
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This review, with its more up-to-date collection of studies, more rigorously 
collected data (from only prospective studies) and more precise time frames 
(which avoid the uncertainty implicit in time-until periods dictated by retrospective 
designs), confirms the broad finding of previous systematic reviews that antibiotic 
exposure results in resistance (1, 19).  
It has been reported previously, that isolation of resistant isolates was strongest 
in the month directly after exposure and remained detectable for up to 12 months 
(1). However, our review provides better and more nuanced estimates of the time 
to decay of antibiotic resistance after exposure, with faster decays than previously 
reported. In addition, we show that the time frame may vary according to antibiotic 
class and bacteria, notwithstanding the limitations of the primary evidence. 
Our search strategy was systematic and transparent, and found studies that had 
not been found in the earlier review of resistance decay (1). Our review also 
provides a higher level of rigour by excluding studies at high risk of bias due to 
confounding variables (such as hospitalisation, device-associated infections and 
persistent infections) and by being careful to align the time periods after antibiotic 
exposure (as subgroup analyses) among the included studies to enable better 
comparisons. 
There are several limitations of this review. First, the unadjusted status of the 
ORs we extracted, rather than simply importing study authors’ adjustments of 
some confounders, threatens to introduce bias from those confounders. There 
are potentially many other confounders. For example, resistance can be acquired 
through contact with other individuals rather than direct antibiotic exposure, 
groups within the included studies may have different baseline risks for 
resistance, resistance sampling was not standardised and indications for 
antibiotic exposure and bacterial load (likely to differ between symptomatic and 
asymptomatic participants, who might be the only carriers of resistance in their 
microbiome, or between children and adults) might affect the development of 
resistance. However, the crude ORs reported differ little from the adjusted values. 
We were not able to investigate any effect of dose or duration of the antibiotic 
exposure on resistance. The quality of how resistance data were analysed and 
reported was poor in some studies, and some authors did not respond to our 
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requests to clarify aspects of their methods and data, which contributes to the 
uncertainty of the review’s estimates. This could be because reporting of 
resistance was not the primary objective in most of the included studies. Finally, 
resistance was reported in most studies as the proportion of resistant isolates, 
which does not take account of the changes in overall bacterial population, which 
is likely to decrease from the antibiotic effect. Consequently, a rise in the 
resistance proportion might disguise a decrease in the absolute numbers of 
resistant bacteria. 
Urgently needed is further research with high-quality placebo-controlled trials that 
measure the numbers of resistant and susceptible isolates and enable 
comparisons of antibiotic dose, duration and class against different bacteria. 
Conclusions 
Antibiotic use increases the consequent isolation of bacterial resistance in 
individuals. The odds of resistance developing and the time of return to bacterial 
susceptibility may vary by antibiotic class. It appears that decay after exposure to 
antibiotics may be faster than previously reported (1) for penicillins against 
respiratory S. pneumoniae, and perhaps H. influenzae, although this may not be 
true for other antibiotics such as macrolides, where resistance might persist 
longer. This may be another factor for clinicians to consider when choosing an 
antibiotic, especially for minor infections. More primary research focussing on 
resistance development and decay is needed to further inform clinical decisions 
and public health policies. 
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Supplementary Material 4. Elaboration on the inclusion and exclusion criteria  
 Inclusion criteria Exclusion criteria Rationale for 
exclusion 
criteria 
Population Symptomatic and 
asymptomatic 
patients (healthy 
people)  
Hospitalised patients 
with infections >48 
hours after admission 
Increased risk 
of colonization 
with drug-
resistant 
bacteria from 
the hospital 
environment 
Hospitalised patients 
with a community 
infection (<48 hours 
from admission) 
Patients with post-
surgery infections 
 Burn-associated 
infections 
 Sample of health care 
workers, medical or 
nursing students with 
medical rotations 
 ICU patients referred 
from hospital wards or 
patients with central-
line associated 
bloodstream 
infections 
High 
probability that 
these patients 
are infected 
with resistant 
bacteria 
 Patients with device-
related infections 
(catheter, implants, 
dialysis-associated 
infections, ventilation-
associated infections) 
Devices are 
more prone to 
infection with 
resistant 
bacteria 
 Patients with 
persistent diseases 
(Tuberculosis, H. 
pylori, Syphilis, 
Pseudomonas 
aeruginosa, 
Mycobacterium 
leprae, Salmonella 
typhi) 
Asymptomatic 
infections that 
remains 
undetected for 
a long 
duration. They 
require 
prolonged 
antibiotic 
treatments 
and it is 
considered 
treatment 
failure if the 
bacterium is 
isolated after 
treatment. 
 >50% of the sample 
are 
Infections due 
to 
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Immunocompromised 
patients 
opportunistic 
bacteria that 
normally does 
not cause 
infections 
 Patients with (Cystic 
fibrosis patients, 
Bronchiectasis, 
cancer patients) 
Comorbidities 
that increase 
the risk of 
infection 
Intervention Any antibiotic 
exposure for any 
infection <14 days 
(Prospective or 
retrospective) 
Long-term antibiotic 
treatment > 2 
continuous weeks 
Higher 
probability of 
killing 
susceptible 
organisms and 
increased risk 
of carriage of 
resistant 
isolates 
Control 
/comparator 
Patients without 
antibiotic exposure 
  
Patients with a 
different antibiotic 
exposure/different 
dose/frequency/route 
of administration 
If there are no before-
after measurement of 
resistance 
 
Outcome Prevalence of 
resistance in 
exposed/unexposed 
patients 
If there are not 
enough data available 
to calculate the Odds 
ratio of resistance in 
participants exposed 
to antibiotics 
compared with those 
without antibiotic 
exposure or before-
after antibiotic 
treatment 
 
 Duplicate isolate 
reporting 
 
Time Time between 
antibiotic exposure 
and isolation of 
resistant organisms 
Studies were 
excluded if there are 
no data available on 
the last know 
antibiotic exposure 
 
Setting Primary care   
General practices   
Outpatient clinics   
Paediatric clinics   
Emergency 
department 
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Supplementary Material 5. Search strategy 
PubMed 
("Drug Resistance"[Mesh] OR Resistance[tiab] OR Resistant[tiab] OR 
Multiresistant[tiab]) 
AND 
("Anti-Bacterial Agents"[Mesh] OR "Macrolides"[Mesh] OR "beta-
Lactams"[Mesh] OR Antibacterial[tiab] OR Antibacterials[tiab] OR 
Antibiotics[tiab] OR Antibiotic[tiab] OR Macrolides[tiab] OR Macrolide[tiab] OR 
beta-Lactams[tiab] OR Antimicrobial[tiab] OR Antimicrobials[tiab] OR 
Penicillin[tiab] OR Methicillin[tiab]  OR ampicillin[tiab] OR 
azithromycin[tiab]  OR Cephalexin[tiab]) 
AND 
("Population Surveillance"[Mesh] OR "Primary Health Care"[Mesh] OR 
"Ambulatory Care"[Mesh] OR "Outpatients"[Mesh]  OR "Community-Acquired 
Infections"[Mesh] OR "Demography"[Mesh] OR "Carrier State"[Mesh] OR 
"Endemic Diseases"[Mesh] OR “Primary care”[tiab] OR “Primary 
healthcare”[tiab] OR “Family practice”[tiab] OR “General practice”[tiab] OR 
Ambulatory[tiab] OR Outpatients[tiab] OR Outpatient[tiab] OR Community[tiab] 
OR Communities[tiab] OR Surveillance[tiab] OR Carrier[tiab] OR Carriage[tiab] 
OR Area[tiab] OR Areas[tiab] OR Region[tiab] OR Regions[tiab] OR 
Demographic[tiab]) 
AND 
("Drug Prescriptions"[Mesh] OR "Prescriptions"[Mesh] OR “therapeutic 
use“[sh] OR  Prescriptions[tiab] OR Prescription[tiab] OR Prescribing[tiab] OR 
Prescribe[tiab] OR Prescribed[tiab] OR Consumption[tiab] OR Courses[tiab] 
OR Course[tiab] OR Programme[tiab] OR Programmes[tiab] OR Dose[tiab] OR 
Doses[tiab] OR Exposure[tiab] OR Isolates[tiab] OR Isolated[tiab] OR Risk[ti]) 
AND 
("Patients"[Mesh] OR “Drug therapy”[sh] OR “Drug effects”[sh] OR 
Microbiology[sh]  OR Treatment[tiab] OR Patient[tiab] OR Patients[tiab] OR 
Patient's[tiab]) 
AND 
(“Randomized Controlled Trial”[pt] OR “Controlled Clinical Trial”[pt] OR 
"Epidemiologic Studies"[Mesh] OR Randomly[tiab] OR Randomised[tiab] OR 
Randomized[tiab] OR Group[tiab] OR Groups[tiab] OR Control[tiab] OR 
Controlled[tiab] OR Case[tiab] OR Cases[tiab] OR Multicenter OR Center[tiab] 
OR Centre[tiab] OR Trial[tiab] OR Trials[tiab] OR Compare[tiab] OR 
Compared[tiab] OR Comparison[tiab] OR Cohort[tiab] OR Observed[tiab] OR 
Observational[tiab] OR Questionnaires[tiab] OR Questionnaires[tiab] OR 
Frequency[tiab] OR Frequencies[tiab] OR Baseline[tiab] OR Modeling[tiab]) 
NOT 
("Hospitals"[Mesh] OR “Inpatients”[Mesh] OR "Cross Infection"[Mesh] OR 
Hospitals[ti] OR Hospital[ti] OR Inpatients[tiab] OR Inpatient[tiab] OR “Cross 
infection”[tiab] OR “Cross infections”[tiab] OR “Hospital acquired”[tiab] OR 
"Hospital infection"[tiab] OR "Hospital infections"[tiab] OR Animal[tiab] OR 
Animals[tiab]) 
NOT 
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(Review[pt] OR Meta Analysis[pt] OR News[pt] OR Comment[pt] OR 
Editorial[pt] OR Letter[pt] OR comment on[ti] OR systematic review[ti] or 
literature review[ti]) 
NOT 
(Animals[Mesh] not (Animals[Mesh] and Humans[Mesh])) 
 
CENTRAL (Cochrane) 
([mh "Drug Resistance"] OR Resistance:ti,ab OR Resistant:ti,ab OR 
Multiresistant:ti,ab) 
AND 
([mh "Anti-Bacterial Agents"] OR [mh "Macrolides"] OR [mh "beta-Lactams"] 
OR Antibacterial:ti,ab OR Antibacterials:ti,ab OR Antibiotics:ti,ab OR 
Antibiotic:ti,ab OR Macrolides:ti,ab OR Macrolide:ti,ab OR beta-Lactams:ti,ab 
OR Antimicrobial:ti,ab OR Antimicrobials:ti,ab OR Penicillin:ti,ab OR 
Methicillin:ti,ab  OR ampicillin:ti,ab OR azithromycin:ti,ab  OR Cephalexin:ti,ab) 
AND 
([mh “Population Surveillance"] OR [mh "Primary Health Care"] OR [mh 
"Ambulatory Care"] OR [mh "Outpatients"]  OR [mh "Community-Acquired 
Infections"] OR [mh "Demography"] OR [mh "Carrier State"] OR [mh "Endemic 
Diseases"] OR “Primary care”:ti,ab OR “Primary healthcare”:ti,ab OR “Family 
practice”:ti,ab OR “General practice”:ti,ab OR Ambulatory:ti,ab OR 
Outpatients:ti,ab OR Outpatient:ti,ab OR Community:ti,ab OR 
Communities:ti,ab OR Surveillance:ti,ab OR Carrier:ti,ab OR Carriage:ti,ab OR 
Area:ti,ab OR Areas:ti,ab OR Region:ti,ab OR Regions:ti,ab OR 
Demographic:ti,ab) 
AND 
([mh "Drug Prescriptions"] OR [mh "Prescriptions"] OR "therapeutic use":kw 
OR  Prescriptions:ti,ab OR Prescription:ti,ab OR Prescribing:ti,ab OR 
Prescribe:ti,ab OR Prescribed:ti,ab OR Consumption:ti,ab OR Courses:ti,ab 
OR Course:ti,ab OR Programme:ti,ab OR Programmes:ti,ab OR Dose:ti,ab OR 
Doses:ti,ab OR Exposure:ti,ab OR Isolates:ti,ab OR Isolated:ti,ab OR Risk:ti) 
AND 
([mh "Patients"] OR "Drug therapy":kw OR "Drug effects":kw OR 
Microbiology:kw  OR Treatment:ti,ab OR Patient:ti,ab OR Patients:ti,ab OR 
Patient’s:ti,ab) 
NOT 
([mh "Hospitals"] OR [mh "Inpatients"] OR [mh "Cross Infection"] OR 
Hospitals:ti OR Hospital:ti OR Inpatients:ti,ab OR Inpatient:ti,ab OR "Cross 
infection":ti,ab OR "Cross infections":ti,ab OR "Hospital acquired":ti,ab OR 
"Hospital infection":ti,ab OR "Hospital infections":ti,ab OR Animal:ti,ab OR 
Animals:ti,ab) 
NOT 
([mh Animals] not ([mh Animals] and [mh Humans])) 
EMBASE 
('Drug Resistance'/exp OR Resistance:ti,ab OR Resistant:ti,ab OR 
Multiresistant:ti,ab) 
AND 
('antibiotic agent'/exp OR 'Macrolide'/exp OR  'beta lactam'/exp OR 
Antibacterial:ti,ab OR Antibacterials:ti,ab OR Antibiotics:ti,ab OR 
Antibiotic:ti,ab OR Macrolides:ti,ab OR Macrolide:ti,ab OR beta-Lactams:ti,ab 
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OR Antimicrobial:ti,ab OR Antimicrobials:ti,ab OR Penicillin:ti,ab OR 
Methicillin:ti,ab  OR ampicillin:ti,ab OR azithromycin:ti,ab  OR Cephalexin:ti,ab) 
AND 
('health survey'/exp OR 'Primary Health Care'/exp OR 'Ambulatory Care’/exp 
OR 'Outpatient'/exp OR 'Community-Acquired Infection'/exp OR 
'Demography'/exp OR 'heterozygote'/exp OR 'Endemic Disease'/exp OR 
“Primary care”:ti,ab OR “Primary healthcare”:ti,ab OR “Family practice”:ti,ab 
OR “General practice”:ti,ab OR Ambulatory:ti,ab OR Outpatients:ti,ab OR 
Outpatient:ti,ab OR Community:ti,ab OR Communities:ti,ab OR 
Surveillance:ti,ab OR Carrier:ti,ab OR Carriage:ti,ab OR Area:ti,ab OR 
Areas:ti,ab OR Region:ti,ab OR Regions:ti,ab OR Demographic:ti,ab) 
AND 
('Prescription'/exp OR 'Prescriptions'/exp OR Prescriptions:ti,ab OR 
Prescription:ti,ab OR Prescribing:ti,ab OR Prescribe:ti,ab OR Prescribed:ti,ab 
OR Consumption:ti,ab OR Courses:ti,ab OR Course:ti,ab OR Programme:ti,ab 
OR Programmes:ti,ab OR Dose:ti,ab OR Doses:ti,ab OR Exposure:ti,ab OR 
Isolates:ti,ab OR Isolated:ti,ab OR Risk:ti) 
AND 
('Patient'/exp OR Patient:ti,ab OR Patients:ti,ab OR Treatment:ti,ab) 
AND 
('Randomized Controlled Trial’:it OR ‘Controlled Clinical Trial’:it OR 
'epidemiology'/exp OR Randomly:ti,ab OR Randomised:ti,ab OR 
Randomized:ti,ab OR Group:ti,ab OR Groups:ti,ab OR Control:ti,ab OR 
Controlled:ti,ab OR Case:ti,ab OR Cases:ti,ab OR Multicenter OR Center:ti,ab 
OR Centre:ti,ab OR Trial:ti,ab OR Trials:ti,ab OR Compare:ti,ab OR 
Compared:ti,ab OR Comparison:ti,ab OR Cohort:ti,ab OR Observed:ti,ab OR 
Observational:ti,ab OR Questionnaires:ti,ab OR Questionnaires:ti,ab OR 
Frequency:ti,ab OR Frequencies:ti,ab OR Baseline:ti,ab OR Modeling:ti,ab) 
NOT 
('Hospitals'/exp OR 'Inpatients'/exp OR 'Cross Infection'/exp OR Hospitals:ti 
OR Hospital:ti OR Inpatients:ti,ab OR Inpatient:ti,ab OR "Cross infection":ti,ab 
OR "Cross infections":ti,ab OR "Hospital acquired":ti,ab OR "Hospital 
infection":ti,ab OR "Hospital infections":ti,ab OR Animal:ti,ab OR Animals:ti,ab) 
NOT 
(Review:it OR Meta Analysis:it OR News:it OR Comment:it OR Editorial:it OR 
Letter:it OR “comment on”:ti OR “systematic review”:ti OR “literature review”:ti) 
NOT 
(‘animal'/exp NOT ('animal'/exp AND 'human'/exp)) 
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Supplementary Material 6. Detailed reasons of exclusion 
Insufficient 
data reported 
No individual patient data reported, only reporting P-
value 
62 
No data on the number of resistant isolates 49 
No data on the number of patients exposed to 
antibiotics 
47 
Time between AB exposure and isolation of resistance 
not reported 
14 
Contacted authors & no response/no full text (conf. 
abstract) 
23 
Ineligible 
participants’ 
criteria 
Hospitalised patients >50% (or hospital associated 
infections, inpatients) 
89 
Patients with persistent infections/device related 
infections/tract abnormalities  
11 
Immunocompromised patients 5 
>50% nursing home residents 1 
Reporting gene mutations, in-vitro resistant isolates 5 
Ineligible 
exposure 
Prolonged antibiotic exposure (>2 weeks of exposure) 33 
Pharmacokinetics of antibiotic exposure 2 
Ineligible 
outcome data 
No before-after outcome data in studies where all 
patients received antibiotic treatment 
11 
Mixed data between resistant and susceptible isolates 
or all patients have resistant isolates 
7 
Ineligible 
study design 
Case series / case reports/reviews/reports 8 
Duplicates 12 
Total 379 
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Supplementary Material 7. Funnel plots of comparison 
Funnel plots of comparison 
Studies investigating before-after antibiotic exposure 
(Respiratory Tract) 
Studies investigating antibiotic exposure with a control 
group (Respiratory Tract) 
Penicillin-class antibiotic exposure and isolation of Resistant-S. pneumonia 
Penicillin-class antibiotic exposure and isolation of Resistant-H. influenzae 
Cephalosporin-class antibiotic exposure and isolation of Resistant-S. pneumonia 
No Data 
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Cephalosporin-class antibiotic exposure and isolation of Resistant- H. influenzae 
 
 
 
 
 
 
 
No Data 
Macrolide-class antibiotic exposure and isolation of Resistant-S. pneumonia 
  
Macrolide -class antibiotic exposure and isolation of Resistant- H. influenzae 
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Studies investigating before-after antibiotic exposure (GIT) Studies investigating antibiotic exposure with a control 
group (GIT) 
Any antibiotic exposure and isolation of Resistant-Enterobacteria 
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Supplementary Material 8. Odds ratio of resistance in other respiratory isolates post exposure to different antibiotic classes 
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Supplementary Material 9. Co-resistance data reported among the included studies 
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Preamble 
The previous study discovered that the quality of how resistance data were 
analysed and reported was poor in some studies. This contributed to the 
uncertainty of the review’s estimates. Although the number of studies examining 
antibiotic resistance is rapidly increasing, an examination of the completeness of 
reporting in prospective studies investigating antibiotic resistance had not 
occurred. Exploring the problem of reporting in a specific content area is often 
done as a way of seeing if an adapted or new reporting guideline is needed to 
assist authors and peer reviewers. This study (Study 4) is the first step towards 
facilitating for better reporting of prospective studies of antibiotic resistance.   
 
This chapter consists of the paper titled “An analysis of reporting quality of 
prospective studies examining community antibiotic use and resistance.”, 
published in Trials journal. It explores the reporting quality of antibiotic resistance 
in prospective primary studies that examined antibiotic use and resistance. 
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Abstract  
Background—Antibiotic resistance is a global problem, but the relationship 
between antibiotic use and resistance development and decay is not well 
understood. This knowledge is best provided by prospective studies, but to be 
useful they must be both conducted and reported well. Little is known about the 
reporting quality of these studies. This study aimed to assess the quality of 
reporting in prospective studies which investigated antibiotic resistance following 
antibiotic exposure in community-based individuals. 
Methods—The quality of reporting of prospective studies (17 randomised trials, 
8 cohort studies) identified in a systematic review of the relationship between 
antibiotic use and resistance were assessed independently by two researchers 
using checklists (one for trials, one for cohort studies) developed from existing 
reporting guidelines for these designs and this field. 
Results—The mean percentage (SD, minimum-maximum) of mandatory items 
that were adequately described by the included studies was 59% for trials (14%, 
36%–84%) and 52% for cohort studies (17%, 13%–70%). Most studies 
adequately described the study background and rationale, the type, combination, 
and duration of the antibiotic intervention, and the sampling procedures followed 
to isolate resistant bacteria. Most studies did not report the incident numbers of 
resistant and susceptible isolates analysed at each time-point. Blinding and 
sample size calculation was inadequately reported in almost half of the trials and 
all cohort studies.  
Conclusions—The quality of reporting in prospective studies investigating the 
association between antibiotic exposure in the community and isolation of 
resistance isolates is variable. Some details were missing in over half of the 
studies, which precludes a complete risk of bias assessment and accurate 
interpretation and synthesis of results. 
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Background 
Antibiotic resistance is a global public health concern, threatening lives by 
jeopardising successful treatment of a vast range of bacterial infections (1, 2). It 
is estimated that 10 million people may die in 2050 because of resistance (3). 
Antibiotic prescribing levels in primary care are high (4, 5), even though for many 
of the conditions for which they are prescribed (such as acute respiratory 
infections), antibiotics provide minimal benefits, and these may not be 
outweighed by the harms of their use (6-10).  
Antibiotic use drives resistance (11-13) and there is some indication that 
resistance decays over time (13).  Knowledge about the association between 
antibiotic use, the development of resistance, and timeframes of potential decay 
is important for informing public health messages, antibiotic resistance 
campaigns, and clinician training. However, evidence syntheses investigating the 
relationship between antibiotic exposure and the development and decay of 
resistance have been limited to two systematic reviews which have included 
mostly studies with retrospective designs (11, 12). Understanding the association 
between antibiotic exposure and isolation of resistance bacteria is best informed 
by prospective study designs. Such designs offer better opportunities to control 
for confounding factors, including more precise time frames of the duration 
between antibiotic exposure and isolation of resistance bacteria which helps to 
avoid the uncertainty that is implicit in ‘time-until’ periods that are dictated by 
retrospective designs. As global concern about resistance increases, an 
increasing number of prospective studies investigating this issue are being 
conducted. 
However, to provide interpretable evidence and enable complete risk of bias 
assessment, these studies need to be reported clearly and comprehensively. 
There are characteristics of studies that measure antibiotic exposure and 
resistance which are not adequately captured by existing reporting checklists and 
researchers may not have adequate awareness of these issues and guidance 
about how to report such studies. We are not aware of any studies which have 
examined the quality of reporting of studies about antibiotic use and resistance. 
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We aimed to assess the completeness of reporting of prospective primary studies 
that examined antibiotic use and resistance.  
Methods 
Selection of included studies 
Studies were included in this study if they had been identified as part of a recently 
published systematic review which assessed the extent of bacterial resistance in 
individuals caused by antibiotic use in primary care, and the rate of decay of 
resistance (13).   
Full details of the systematic review search are available elsewhere (13). Briefly, 
we searched PubMed, EMBASE, and the Cochrane Central Register of 
Controlled Trials from inception until the first week of May 2017, using MeSH 
terms, keywords, and forward and backward citation searches. We included 
randomised controlled trials and prospective cohort studies which compared 
antibiotic-exposed patients in the community against controls. Our outcome was 
the prevalence of resistance bacteria over time.  
Assessment of the quality of reporting of included studies 
For the present study, we developed two assessment checklists (one for trials 
and one for prospective cohort studies), based on existing reporting guidelines 
relevant to these study designs and this field. For trials, the relevant guideline 
was the Consolidated Standards of Reporting Trials statement (CONSORT) (14); 
for cohort studies, the relevant guidelines were Strengthening the Reporting of 
Observational studies in Epidemiology (STROBE) (15) and its extension for 
optimising reporting of epidemiological studies in Antimicrobial Stewardship 
(STROBE-AMS) (16). Additional reporting recommendations that are relevant to 
both study types include the Template for Intervention Description and 
Replication (TIDieR (17)) items and those specific to resistance reporting in 
systematic reviews of antibiotic interventions (18). 
Informed by our experience from completing the systematic review, several items 
necessary for the accurate interpretation of results were added to the checklists. 
The resultant checklists were piloted with 4 epidemiologists and 4 antibiotic 
resistance researchers who used them to assess the quality of reporting of a 
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small number of eligible studies. Following this, minor modifications were made 
to the grouping of the items, and the explanatory wording of some of the 
additional items. The final version of trial checklist had 89 items and the cohort 
checklist had 81 items.  
Two researchers (MB and AMS) then used the checklists to independently 
assess the quality of reporting of each included study. Each item was rated Yes 
(if the study adequately described the item), No (if it did not), or Not applicable. 
Agreement between assessors was reached through discussion after small 
batches of 5 studies were rated, and discrepancies resolved through discussion 
with a third researcher (TH or CDM). The agreement between the two assessors 
was not calculated. The complete checklists with item descriptions and the source 
of each item are available in Supplementary Materials 10 and 11. 
Data analysis 
Data were analysed using Microsoft Excel® 2016 and descriptive statistics were 
calculated.  
Results 
The sample of articles consisted of 17 randomised controlled trials and 8 
prospective cohort studies. The trials primarily assessed the risk of isolation of 
post-treatment carriage of resistant bacteria. They were published from 1982 to 
2016 and conducted in 10 countries. The cohort studies assessed changes in 
resistance patterns before and after antibiotic use. They were published from 
1988 to 2008 and from 7 countries (the full list of included articles is shown in 
Supplementary Material 12). 
Completeness of reporting - trials 
For the 17 trials, 70 mandatory items and an additional 19 'if applicable' items 
were scored.  Twelve (17%) mandatory items were reported by all trials; one item 
(describing other organisms susceptible to the exposed antimicrobial or same 
class) was not reported by any trials. The mean percentage (SD, minimum-
maximum) of the mandatory items that were adequately described by the trials 
was 59% (14%, 36%–84%) (Fig. 10). Supplementary Material 13 shows the 
percentages of trials that adequately described each item including the ‘if 
Chapter 6: Reporting quality of antibiotic resistance studies 
[131] 
applicable’ items and Supplementary Material 14 shows the percentage of items 
adequately described by each trial. 
The items that were most commonly reported include those about: study 
background (all trials provided the study rationale and described any previous in 
vivo and/or in vitro studies); intervention (most trials adequately described the 
type of antibiotics, duration and dose); and sampling (almost all trials adequately 
reported the sampling procedures followed for isolating resistant isolates 
including the site, number of samples per person, and sampling period).  
Items that were poorly reported by many trials include those describing the 
sample size, randomisation, blinding, and the results. Almost half of the trials 
reported the sample size determination, and over half of the trials poorly 
described the methods used for randomisation and allocation (including the 
person/s responsible for generating the random allocation sequence, and the 
steps taken to conceal the randomisation sequence). Blinding reporting was 
incomplete in almost half of the trials and only one study reported blinding of 
microbiologists to the time of sampling. Many items describing the results were 
missing in the majority of the trials, including key details such as: the numbers 
analysed at nominated time-points, particularly the number of isolates susceptible 
to the intervention or comparator (if applicable); and the number of participants 
with sterile swabs (clean-catch swabs) or resistance /susceptibility among other 
organisms (other than the index pathogen) isolated from other body site (other 
than the system/site of interest). 
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Fig. 10. Quality of reporting, % of RCTs meeting each item (studies= 17, 
mandatory items =70) 
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Completeness of reporting - Cohort studies  
In the 8 cohort studies, 63 mandatory items and an additional 19 ‘if applicable’ 
items were scored: 7 (11%) mandatory items were reported by all cohort studies; 
8 (13%) were not reported by any. The mean percentage (SD, minimum-
maximum) of the mandatory items that were adequately described by the studies 
was 52% (17%, 13%– 70%) (Fig. 11). Supplementary Material 15 shows the 
percentage of cohort studies that adequately described each item including the 
‘if applicable’ items and Supplementary Material 16 shows the percentage of 
items adequately described by each study. 
The items most commonly reported were those about the: study background 
(most described specific objectives and study rationale); outcome measures 
(most defined each measure and reported when each was measured); and 
sampling (most studies adequately described the sampling procedures used, 
including the site, number of samples per person, and sampling period). Items 
that were poorly reported were those describing the sample size, measurement 
and results. None of the studies reported how their sample size was determined 
and none reported if resistance was measured by an independent laboratory or 
if the microbiologists were blinded. As with the trials, many key details about the 
numbers analysed were missing, such as the number of susceptible isolates to 
antibiotic exposure analysed at each of the nominated time-points, along with the 
resistance/susceptibility among other organisms isolated from another body site.  
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Fig. 11. Quality of reporting, % of Cohort studies meeting each item (studies= 8, 
mandatory items =63) 
Chapter 6: Reporting quality of antibiotic resistance studies 
[137] 
Discussion 
The quality of reporting of prospective studies examining antibiotic use and 
resistance varied in this study. Some aspects of the studies (such as the sampling 
procedures used and rationale for the study) were described in most, but some 
details were missing in many studies. Some of the missing items, such as those 
about blinding or the numbers analysed, are particularly important for assessing 
a study’s risk of bias and interpreting its results accurately. 
Few studies reported the incident numbers of both resistant and susceptible 
isolates analysed at each time-point (and for both the intervention and/or 
comparator groups), and only one study reported the isolation of resistant isolates 
from body sites other than the target site/system. This may be as important to 
know as the resistance in the originally infected site, from the point of view of 
antibiotic resistance generation in the microbiome, and hence in the community 
at large. Similarly, most studies only reported resistance to the class of antibiotic 
used, although some studies also reported resistance to other antibiotic classes 
– a possibly important omission because of induced co-resistance to antibiotics 
from different classes (19).   
Reporting of how and whether blinding occurred was inadequate in almost half of 
the studies. Only one study reported whether the microbiologist was blinded to 
the time of sampling. Data on changes in resistance over time could be biased if 
those responsible for measuring resistance are not blinded to the time of 
sampling. As with other aspects of methods reporting, if a study does not describe 
a process, a reader cannot be sure if the process did not occur or was just not 
reported. This uncertainty impedes risk of bias assessment and decreases the 
confidence in the reported results.  
While describing a study with sufficient detail to enable replication and 
interpretation of results is good scientific practice, many authors are not aware of 
all the details that need to be reported to sufficiently describe a study. To assist 
authors with comprehensively describing studies, reporting guidelines have been 
developed. However, for our sample of included studies, the impact of reporting 
guidelines would have been minimal, as most (88%) of the included cohort 
studies were published before the release of the STROBE reporting guidelines 
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(and all before the STROBE-AMS publication), and all but one of the included 
trials were published before the 2010 CONSORT statement, although most 
(except 3) were published before the 1996 CONSORT statement (20).  
As our sample of studies is limited to those included in a systematic review of 
antibiotic resistance in individuals who were prescribed antibiotics in primary 
care, this may limit the generalisability of results beyond this setting. Additionally, 
the checklists used to assess the studies were modified from existing checklists 
and informed by the pragmatic experience of researchers assessing and 
synthesising these types of studies – the modified checklist have not been 
formally assessed. However, a strength of this study is the independent 
assessment of the included studies by two authors. 
Conclusion 
In this study of the reporting quality of prospective studies examining antibiotic 
use and resistance, just over half of the mandatory checklist items were 
adequately described for the randomised trials and cohort studies included. 
Some items (such as the type, combination, and duration of the antibiotic 
intervention, and the sampling procedures used to isolate resistant bacteria) were 
adequately described by most studies, whereas other details (such as the 
incident numbers of resistant and susceptible isolates analysed at each time-
point) were not described by most. Improving the quality of reporting of future 
studies which measure antibiotic resistance is necessary to aid accurate 
synthesis and interpretation of results. Better reporting may be facilitated by a 
reporting checklist, which is created following the recommendations for 
developing reporting guidelines (21), that is specific to prospective studies of 
antibiotic use and resistance. This will help to improve the quality of reporting 
available to the research community, clinicians, and policy makers. 
Declarations 
Acknowledgements: We kindly thank our colleagues who took part in piloting the 
checklists. 
Funding: Funding for a PhD scholarship for the lead author was provided by the 
Australian National Health and Medical Research Council (#1044904), which had 
Chapter 6: Reporting quality of antibiotic resistance studies 
[139] 
no role in study design, data collection, data analysis, data interpretation, or 
writing of the report.  
Availability of data and materials: The datasets used and/or analysed during the 
current study are available from the corresponding author on reasonable request. 
Authors’ contributions: MB, CDM, and TH designed the study. MB and AMS 
performed data extraction and quality assessment. MB analysed the data and 
designed the figures. MB drafted the original manuscript and AMS, TH and CDM 
contributed to writing and revising the manuscript. All authors revised and 
approved the final manuscript.  
Ethics approval and consent to participate: Not applicable 
Consent for publication: Not applicable 
Competing interests: The authors declare that they have no competing interests. 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[140] 
References 
1. WHO. Antimicrobial resistance global report on surveillance. Geneva World Health
Organization 2014. [cited January 18, 2018]. Available from:
http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.
2. WHO. Global antimicrobial resistance surveillance system (GLASS) report: Early
implementation 2016-2017. Geneva: World Health Organization; 2017. [cited January
18, 2018]. Available from: http://www.who.int/glass/resources/publications/early-
implementation-report/en/.
3. O’Neill J. Antibiotic resistance: Tackling drug-resistant infections globally: Final report
and recommendations.; 2016 18 June 2018. Available from: https://amr-
review.org/Publications.html.
4. Del Mar C, Glasziou P, Lowe JB, van Driel ML, Hoffmann T, Beller E. Addressing
antibiotic resistance - focusing on acute respiratory infections in primary care. Aust Fam
Physician. 2012;41(11):839-40. https://www.ncbi.nlm.nih.gov/pubmed/23145411.
5. Gulliford MC, Dregan A, Moore MV, Ashworth M, Staa T, McCann G, et al. Continued
high rates of antibiotic prescribing to adults with respiratory tract infection: Survey of
568 UK general practices. BMJ Open. 2014;4(10):e006245. DOI: 10.1136/bmjopen-
2014-006245.
6. Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW, Jr., Makela
M. Antibiotics for acute maxillary sinusitis in adults. Cochrane Database Syst Rev.
2014;2(2):CD000243. DOI: 10.1002/14651858.CD000243.pub3.
7. Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis.
Cochrane Database Syst Rev. 2013;6(6):CD000247. DOI:
10.1002/14651858.CD000247.pub3.
8. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane
Database Syst Rev. 2014;3(3):CD000245. DOI: 10.1002/14651858.CD000245.pub3.
9. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database
Syst Rev. 2013;11(11):CD000023. DOI: 10.1002/14651858.CD000023.pub4.
10. Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute
otitis media in children. Cochrane Database Syst Rev. 2013;1(1):CD000219. DOI:
10.1002/14651858.CD000219.pub3.
11. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and
meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC
Infect Dis. 2014;14:13. DOI: 10.1186/1471-2334-14-13.
12. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in
primary care on antimicrobial resistance in individual patients: Systematic review and
meta-analysis. BMJ. 2010;340:c2096. DOI: 10.1136/bmj.c2096.
13. Bakhit M, Hoffmann T, Scott AM, Beller E, Rathbone J, Del Mar C. Resistance decay in
individuals after antibiotic exposure in primary care: A systematic review and meta-
analysis. BMC Med. 2018;16(1):126. DOI: 10.1186/s12916-018-1109-4.
14. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for
reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI:
10.1136/bmj.c332.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
strengthening the reporting of observational studies in epidemiology (STROBE)
statement: Guidelines for reporting observational studies. The Lancet.
2007;370(9596):1453-7. DOI: 10.1016/s0140-6736(07)61602-x.
16. Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schroder W, et al.
STROBE-AMS: Recommendations to optimise reporting of epidemiological studies on
antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ
Open. 2016;6(2):e010134. DOI: 10.1136/bmjopen-2015-010134.
Chapter 6: Reporting quality of antibiotic resistance studies 
[141] 
17. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better 
reporting of interventions: template for intervention description and replication (TIDieR) 
checklist and guide. BMJ. 2014;348:g1687. DOI: 10.1136/bmj.g1687. 
18. Leibovici L, Paul M, Garner P, Sinclair DJ, Afshari A, Pace NL, et al. Addressing 
resistance to antibiotics in systematic reviews of antibiotic interventions. J Antimicrob 
Chemother. 2016;71(9):2367-9. DOI: 10.1093/jac/dkw135. 
19. Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without 
antibiotics? The pensieres antibiotic resistance call to action. Antimicrob Resist Infect 
Control. 2012;1(1):11. DOI: 10.1186/2047-2994-1-11. 
20. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of 
reporting of randomized controlled trials: The CONSORT statement. JAMA. 
1996;276(8):637-9. https://www.ncbi.nlm.nih.gov/pubmed/8773637. 
21. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research 
reporting guidelines. PLoS Med. 2010;7(2):e1000217. DOI: 
10.1371/journal.pmed.1000217. 
 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[142] 
Supplementary material 
Published with article presented in Chapter 6 (Study 4) 
https://doi.org/10.1186/s13063-018-3040-6  
The supplementary materials have been reproduced in this thesis under the terms of the Creative 
Commons Attribution-NonCommercial (CC BY-NC 4.0) license. 
http://creativecommons.org/licenses/by/4.0/ 
Chapter 6: Reporting quality of antibiotic resistance studies 
[143] 
Supplementary Material 10. Checklist used to assess RCTs and source of 
each item. https://doi.org/10.6084/m9.figshare.7391855.v1    
Chapter 6: Reporting quality of antibiotic resistance studies 
[144] 
 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[145] 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[146] 
Supplementary Material 11. Checklist used to assess cohort studies and source 
of each item. https://doi.org/10.6084/m9.figshare.7391864.v1   
Chapter 6: Reporting quality of antibiotic resistance studies 
[147] 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[148] 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[149] 
Supplementary Material 12. List of studies included in the systematic review 
and assessed for their quality. https://doi.org/10.6084/m9.figshare.7391876.v1  
Chapter 6: Reporting quality of antibiotic resistance studies 
[150] 
 
Chapter 6: Reporting quality of antibiotic resistance studies 
[151] 
Supplementary Material 13. Quality of reporting, % of RCTs meeting each 
item (studies= 17, including if applicable items)  
https://doi.org/10.6084/m9.figshare.7391891.v1   
Chapter 6: Reporting quality of antibiotic resistance studies 
[152] 
 
 
 
 
 
Chapter 6: Reporting quality of antibiotic resistance studies 
[153] 
Supplementary Material 14. Quality of reporting, % of items described by each 
trial (studies= 17, mandatory items= 70) 
 https://doi.org/10.6084/m9.figshare.7391906.v1  
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[154] 
Supplementary Material 15. Quality of reporting, % of cohort studies meeting 
each item (studies= 8, including if applicable items) 
 https://doi.org/10.6084/m9.figshare.7391918.v1  
 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[155] 
 
  
Chapter 6: Reporting quality of antibiotic resistance studies 
[156] 
Supplementary Material 16. Quality of reporting, % of items described by each 
cohort study (studies= 8, mandatory items= 63) 
https://doi.org/10.6084/m9.figshare.7391927.v1  
 
 
 
 
 
 
Chapter 7 
 
General Discussion 
 
  
Chapter 7: Discussion 
[158] 
Preamble 
 
This chapter draws together the findings and novel contributions of all four 
research studies within the broader scope of the aims of the whole thesis. It also 
discusses the implications of these findings for clinical practice, policy makers 
and future research.  
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The key aims of this thesis were to explore: 1) patient-clinician communication of 
antibiotic benefits and harms, including antibiotic resistance, during ARI 
consultations; 2) patients’ understanding of antibiotic resistance, and aspects of 
it, such as resistance decay and spread among those who live in close proximity; 
and how these influenced patients’ attitudes towards antibiotic use; and 3) to 
update the current evidence about resistance development and decay. The four 
studies presented in this thesis (Chapters 3-6) explored these key objectives 
through the focused research questions presented in Chapter 1. The thesis 
makes an original contribution to the evidence behind resistance decay and 
furthers understanding of the elements of the communication of antibiotic benefits 
and harms (including antibiotic resistance) within GP consultations with patients 
with ARIs. By drawing together these research findings, this chapter identifies 
implications for clinical practice, the conduct of resistance research, and provides 
some recommendations for policy.  
Overview of the problem  
As outlined in Chapter 2, antibiotic resistance is a growing global public health 
crisis (1). Antibiotic resistance emerges as a direct result of individual antibiotic 
use (2-4), human-human transmission from other family and household members 
(5), or through interaction with the environment (6-8). Antibiotic resistance 
increases patients’ morbidity and mortality (9), healthcare resource utilisation (10, 
11), and has an enormous economic impact (12).  
Antibiotics are overused and abused, particularly in primary care (13). In 
Australia, over 30 million antibiotic prescriptions were dispensed in 2015 (14, 15). 
More than 60% of patients consulting in primary care with an ARI received an 
antibiotic, despite evidence from systematic reviews that antibiotics have 
marginal benefits for most ARIs (16-23). Causes for this overuse include both 
clinician and patient-related factors, such as indifference to learning more about 
reducing antibiotic prescribing in ARI management (24), diagnostic uncertainty 
(25-27), patients’ perceived demand of antibiotics (26, 28, 29), and consultation 
time pressure (30).   
Several strategies targeting the previously mentioned factors have been 
promoted to reduce antibiotic use (31). One of these is better communication, 
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such as through shared decision making (SDM) (32). Consultations for ARIs are 
especially suitable for SDM because of the delicate balance between antibiotic 
benefits and harms, and people’s misperceptions of the need for and benefits of 
antibiotics (33). Antibiotic resistance is an unusual harm as it does not affect 
individuals during their current illness, but may affect the course of treatments for 
their future illnesses of the same (or other) infection. Moreover, individuals may 
spread resistance strains to those who live in close proximity (such as family 
members) and the wider community. 
Summary of thesis findings 
Patient-clinician communication of antibiotic treatment for ARIs 
Study 1 (Chapter 3) examined the extent of shared decision making in ARI 
consultations, including if and how clinicians communicated about antibiotic 
benefits and harms. In addition, the study explored whether specifically 
developed decision aids for common ARIs (sore throat, acute bronchitis and 
acute otitis media) were used when available and if they supported clinicians in 
facilitating shared decision making and having a balanced discussion about 
antibiotic benefits and harms with their patients. 
This study found that during routine clinical consultations with ARI patients, 
clinicians generally poorly communicate antibiotic benefits and harms, with little 
mention or explanation about antibiotic resistance as a possible risk. Clinicians 
discussed antibiotic benefits and harms more frequently and more 
comprehensively, and included antibiotic resistance as one of the potential harms 
of using antibiotics, when decision aids were used. 
Information provision by clinicians is necessary to enable patients to make an 
informed decision. Part of this includes having a balanced benefit-harm 
discussion with their patients. Study 1 suggests that using decision aids can help 
facilitate SDM within consultations, improving communication about antibiotic 
benefits and harms, including antibiotic resistance in the discussion of antibiotic 
harms.  
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Patients’ understanding of aspects of antibiotic resistance and its influence on 
attitudes to antibiotic use 
Study 2 (Chapter 4) was a qualitative analysis conducted in a sub-sample of 
patients with ARIs recruited in Study 1. It explored patients’ understanding of 
antibiotic resistance, aspects of resistance such as resistance decay and spread, 
and patients’ attitudes towards antibiotic use. This study is original as no previous 
research has examined patients’ understanding of antibiotic resistance decay or 
spread or influence of this knowledge on attitude about antibiotic use.  
As outlined in Chapter 4, five major themes emerged from the thematic analysis 
of the qualitative interviews. The analysis showed that participants’ 
understanding of many aspects of antibiotic resistance was limited. Although 
participants generally understood the link between antibiotic use and developing 
antibiotic resistance, they were confused about the nature of antibiotic resistance: 
most believed that resistance does not affect the individual. Most participants 
were not aware that resistance can decay over time, and among those who were, 
the estimate of the time to decay were wide (from days to decades). Awareness 
that resistance could be transmitted among family members was low. After an 
explanation from the interviewer about resistance decay and its transmission 
between people who live in close proximity, some participants indicated that 
knowing this would alter their future use of antibiotics by not taking them for minor 
infections. Another finding is that patients with personal experience of antibiotic 
resistance were the most reluctant to use them again; such participants felt 
strongly about reserving their use for serious illness or only when needed. 
Evidence about resistance development and decay 
Previous research had reported that antibiotic resistance takes up to 12 months 
to decay from the maximum directly after antibiotic exposure (4). However, the 
updated and methodologically more rigorous review in Study 3 (Chapter 5) 
showed that antibiotic resistance decays faster than this. Antibiotic resistance 
increased immediately after antibiotic exposure with different odds of isolating 
resistance strains differing by the type of antibiotic exposure and bacterium (Fig. 
7 to 9). Although Study 3 showed that resistance decays with time, the paucity of 
studies investigating this meant only specific bacteria such as S. pneumonia and 
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H. influenzae and exposure to specific antibiotic classes, such as penicillins and 
cephalosporins could be reported. The original contribution of this review is that 
it is the most comprehensive systematic review, which focused solely on studies 
with prospective designs reporting antibiotic resistance after exposure to 
antibiotics in primary care.  
The review highlighted two main issues about the existing research: 1) paucity of 
evidence investigating resistance decay; and 2) incomplete reporting of antibiotic 
resistance in the included studies. Thus, further exploration of the quality of 
reporting against the currently available reporting guidelines was conducted in 
Study 4 (Chapter 6). 
Reporting quality of antibiotic resistance studies 
Study 4 identified deficiencies in the description of aspects of the methods such 
as blinding and sample size determination. Moreover, crucial details about 
antibiotic resistance reporting, such as the incident numbers of patients or 
isolates analysed at each bacterial isolation time point were among the most 
poorly reported items. Incomplete reporting of trials and cohort studies hinders 
the interpretation and use of results in clinical practice, further research, and 
meta-analysis.  
Strengths and limitations of the thesis  
Each study in this thesis has strengths and limitations which have already been 
discussed in the preceding chapters. A summary of these is listed below in Table 
6. 
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Table 6. Strengths and limitations of individual studies in the thesis 
 Strengths  Limitations 
Study 1 
(Observational 
study, Chapter 
3) 
 Minimised bias as 
clinicians did not choose 
which consultations to 
record. 
 Two independent raters 
scored the consultations. 
  Not a true randomised trial. 
 A small number of 
consultations. 
 GPs self-selected to 
participate in the study. 
 Presence of an audio 
recorder during the 
consultation and the 
researcher in the waiting 
room (possible Hawthorne 
effect). 
 Possibly un-representative 
sample. 
Study 2 
(Qualitative 
study, Chapter 
4) 
 The first study to explore 
patients’ knowledge 
about the potential for 
antibiotic resistant 
organisms to spread 
between people in close 
proximity and that 
antibiotic resistance 
decays over time. 
 Thematic analysis was 
done by two researchers 
independently. 
  The risk that the knowledge of 
antibiotic resistance was 
influenced by GPs’ use of a 
patient decision aid for a 
small number of participants. 
 Participants did not have the 
opportunity to provide 
feedback on the themes 
derived from the interviews. 
Study 3 
(Systematic 
review and 
meta-analysis, 
Chapter 5) 
 Systematic and 
transparent search 
strategy. 
 Studies with 
retrospective designs 
posing a high risk of bias 
were excluded. 
 Reporting of time to 
decay periods after 
antibiotic exposure were 
aligned across the 
different bacteria and 
antibiotic classes to 
enable better 
comparisons. 
  Extraction of unadjusted 
status of the odds ratios from 
the included studies vs study 
authors’ altered some 
estimates. 
 Multiple confounders other 
than antibiotic exposure might 
affect the development of 
resistance within individuals 
and the review could not 
examine this. 
 Poor reporting of how 
resistance data were 
analysed.  
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 Some authors did not 
respond to requests to clarify 
aspects of their methods and 
data. 
Study 4 
(Quality of 
reporting 
study, Chapter 
6) 
 The first study to 
examine the quality of 
reporting of prospective 
studies which have 
measured antibiotic 
resistance.  
 Two researchers 
independently performed 
the data extraction. 
  Included studies are limited to 
those included in Study 3 
 Modified checklists were not 
formally assessed. 
 
The broad and inclusive nature of data collection processes (e.g. two 
independent reviewers/raters/coders for each study, rigorous systematic 
searching, and for participant recruitment) are common strengths across the 
studies. Consequently, this thesis has the key strength of providing a broad 
picture of the current state of evidence for antibiotic resistance decay, patient-
clinician communication about antibiotic benefits and harms, and patients’ 
understanding of and attitude towards aspects of antibiotic resistance for ARIs. 
Additionally, the use of rigorous study methodologies and standardised reporting 
guidelines and risk of bias tools (COREQ checklist, PRISMA statement, 
Cochrane Risk of Bias tool, ROBINS-I tool, STROBE statement and its extension 
STROBE-AMS, TIDieR checklist, and CONSORT statement) assists this thesis 
to make a valuable contribution to the current body of evidence. 
The main limitation in the implications for the findings of this thesis derives largely 
from the restricted number of participants and study sites in the primary research 
studies, which risks the generalisability of the study results.  
Implications and recommendations of findings for clinical practice and 
policy 
Antibiotic resistance presents a threat to public health, the safety and efficacy of 
health interventions and can lead to increased morbidity and mortality and 
healthcare-associated expenses (9, 12). National strategies tackling antibiotic 
resistance through antibiotic stewardship programs are an important part of the 
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approach to preserving the effectiveness of antibiotics (34). From the findings of 
this thesis, these implications and recommendations for clinical practice and 
policy have been derived: 
Recommendation 1: Efforts to promote SDM within consultations for ARIs in primary 
care should be continued, particularly by using decision aids.  
Several interventions which aim to facilitate SDM have been shown to be effective 
in reducing antibiotic prescribing in primary care (32). However, in the Australian 
general practice context, brief decision aids may be the most likely to be 
implemented, as existing interventions are difficult to adopt (costly and more time 
consuming) (35).  Thus as part of addressing the crisis of antibiotic resistance, it 
is worth exploring further different ways to facilitate SDM. This thesis (Study 1, 
Chapter 3) provides support for the growing movement towards implementation 
of SDM within consultations for ARIs as it found that utilising a decision aid 
facilitated elements of SDM and more comprehensive communication about 
antibiotic benefits and harms. An important caveat to note while interpreting the 
study findings is that although the practices were participating in a randomised 
trial, this substudy was not a randomised trial. However, the logistics of 
measuring SDM in every consultation in a randomised trial made this not feasible. 
It is prohibitively expensive to screen and gain consent from every patient who 
visits each GP in every practice for the duration of the main trial.  
With or without these specific decision aids, clinicians should aim to have 
consultations with their patients that help them to reach an informed and 
collaborative decision about the use of antibiotics for ARIs.      
Recommendation 2: Public health messages could incorporate messages that target 
patients’ misunderstandings about: what antibiotic resistance is; individual contribution 
to its development; individual implications; its spread between family members; and 
perhaps its decay with time. 
Study 2 revealed that people attending their GP had poor knowledge about 
antibiotic resistance, specifically its spread among people who live in close 
proximity, and that antibiotic resistance decays with time from the maximum 
directly after antibiotic exposure. In some participants, knowing that resistance 
decays over time if antibiotics are not used, provided hope for conserving 
antibiotics, and for others, learning that antibiotic resistance can be transmitted 
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among people who live in close proximity such as family members, was a reason 
not to use them. When considered together, the findings from Studies 2 and 3 
highlight the potential to further research and consider providing information that: 
1) resistance that will occur after exposure to even a single antibiotic course and 
that antibiotics might not work until decay occurs (if serious illness develops); and 
2) resistance could be transmitted between people who live in close proximity to 
the patient before prescribing antibiotics for minor infections such as ARIs. 
However, the optimal information about antibiotic use and resistance to include 
in public health messages, and clinical consultations, needs further testing (see 
implications for future research). 
Recommendation 3: That antibiotic resistance decays at different rates for different 
antibiotic classes and bacteria than previously reported, should be considered by 
clinicians when choosing which (if any) antibiotics for their patients. 
Since 2010, the message about antibiotic resistance has been that it takes up to 
12 months to decay in community-based individuals following antibiotic exposure 
(4). However, Study 3 showed this might not be true for all bacteria or following 
exposure to the different antibiotic classes. The review found that it takes up to 
one month for resistant strains of S. pneumonia bacteria to decay after individual 
exposure to penicillin- or cephalosporin-class antibiotics. The paucity of evidence 
limited exploration of the decay behaviour following exposure to other classes. 
However, the limited evidence in studies which reported resistance after 
exposure to macrolides showed that it might take up to 6 months for resistant 
strains of S. pneumonia to decay. If clinicians were aware of and considered this 
information and prescribed antibiotic classes associated with quicker decay, this 
may reduce the emergence of resistance within the community. This information 
is important for policy makers and government advisory boards (such as The 
Department of Health and NPS MedicineWise). These organisations could use 
these findings in coordinated strategies and interventions to promote the use of 
antibiotics associated with quicker decay.    
Recommendation 4: Trials investigating the clinical efficacy of any antibiotic 
interventions should report antibiotic resistance as a key harm of antibiotics. 
Although many studies are published every year investigating the clinical efficacy 
of different antibiotic classes in the treatment of different infections, few report 
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antibiotic resistance as a direct harm from using antibiotics. Even if when it is 
reported, as the findings from Study 4 show, it is not reported optimally. 
Implications of findings for future research  
Following the research conducted for this thesis, several unanswered questions 
have emerged. These are briefly outlined below and should be addressed in 
future research: 
1. Does knowledge about resistance decay influences GPs’ attitude towards 
antibiotic prescribing for ARIs? 
In Chapter 4, patients’ understanding of antibiotic resistance and its 
aspects was examined. However, examining clinicians’ knowledge about 
resistance decay might influence their attitudes towards antibiotic 
prescribing. As described in Chapter 2, many clinicians believe that they 
do not contribute to the problem of antibiotic resistance and that it is a 
hospital-based problem rather than a community problem (36). Other 
qualitative research has suggested that linking clinicians’ prescribing with 
local resistance rates may motivate clinicians to change their prescribing 
behaviour (37, 38). It has been suggested that future research 
interventions that aim to reduce antibiotic prescribing should target 
clinicians’ perception of antibiotic benefits to their patients, which is 
outweighed by the individual and societal harms of antibiotic resistance 
(38).    
Providing clinicians with information about resistance development after 
antibiotic use in community individuals, might, or might not, change their 
prescribing behaviour. The results from the systematic review and meta-
analysis (Chapter 5) showed that time to resistance decay is faster than 
previously reported (2). It is unknown if this knowledge would mitigate or 
add to the problem of inappropriate antibiotic prescribing. Future research 
could shed light on how this might influence antibiotic prescribing.     
2. How does personal experience of antibiotic resistance influence attitudes 
towards the antibiotic use of individual patients? 
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The findings of Study 2 (Chapter 4) suggested that patients who had 
personal experience with antibiotic resistance were the most reluctant to 
use them again, instead preferring to reserve their use for serious 
illnesses. This area has not been sufficiently examined. It might assist in 
developing public health messages or information that can be used in 
consultations. In a survey among the general population in Germany, 
people who knew someone suffering from multi-drug resistant organisms 
demanded more information on antibiotic resistance from their GP and 
fewer antibiotics compared to those who did not know someone with 
antibiotic resistance (39). 
3. What optimal information about antibiotic use and resistance should be 
included in public health messages? 
This future research area arises from Study 2 and the literature review in 
Chapter 2. In a review of the characteristics and outcomes of large-scale 
public health campaigns aimed at improving the use of antibiotics (40), 
campaigns promoted key messages that antibiotic resistance is a problem 
and that viruses cause most respiratory infections. However, campaigns 
did not convey information about antibiotic harms, and it was not clear 
which campaign elements were the reason behind the change of 
behaviour that led to a reduction in antibiotic use (40). It is also unknown 
if a greater reduction in antibiotic use could be achieved if different or 
additional elements and messages were incorporated into campaigns. 
Study 2 showed that information about aspects of antibiotic resistance 
(such as resistance decay and spread) might contribute to altering 
people’s attitude towards antibiotic use, at least for minor infections. There 
is a need to identify areas with a paradoxical effect on the public’s attitude 
towards antibiotic use, ensuring optimal information about antibiotic use 
and resistance can be included in public health messages.  
4. How to improve the reporting quality of antibiotic resistance research? 
This issue arises from Studies 3 and 4 (Chapter 5 and 6). Many of the 
studies that reported resistance after community antibiotic exposure did 
not report key details. For example, most studies did not report the incident 
numbers of resistant and susceptible isolates analysed at each time-point, 
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and blinding was inadequately reported in just over half of the trials and all 
prospective cohort studies.  
Although guidelines are available for optimising reporting of 
epidemiological studies in Antimicrobial Stewardship (STROBE-AMS) 
(41), they are not designed for use with prospective design studies. 
Moreover, there are concerns about the generalisability of STROBE-AMS. 
The authors describe limiting their literature review to only articles which 
analysed the association between antibiotic exposure and the acquisition 
of Methicillin-resistant Staphylococcus aureus (MRSA) and/or multidrug-
resistant Acinetobacter baumannii. 
Collecting and aggregating expert opinion using recommended methods 
(42) to develop a better and globally endorsed reporting checklist maybe 
worthwhile. The existence of a reporting guideline and checklist is not 
sufficient on its own to improve reporting quality. However, endorsement 
of guideline use and adequate reporting of antibiotic resistance studies is 
needed by researchers, peer-reviewers, and journal editors of relevant 
journals.  
5. Is time to resistance decay different after exposure to different antibiotic 
classes? 
Study 3 showed that the behaviour of resistance decay varies according 
to the class of antibiotic exposure and type of bacterium. However, the 
paucity of available data limited the investigation of resistance decay 
among other classes and bacteria beyond what was described in Study 3. 
Many studies investigating resistance reversibility are laboratory-bench-
top, examining the ‘fitness costs’ for bacteria required for antibiotic 
reversibility to occur (43). However, more RCTs are required to empirically 
test the decay of antibiotic resistance in patients, because of the 
complexity of bacteria population dynamics. These would enable the 
enhancement of antibiotic therapeutic guidelines to accommodate the 
potential of different antibiotic resistance generation among different 
antibiotic-infection dyads. Consequently, as previously described, guiding 
future antimicrobial stewardship programs to promote the use of antibiotics 
associated with quicker decay.  
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Conclusion 
This thesis highlighted the need for enhanced communication between clinicians 
and patients with ARIs about antibiotic use, including a balanced conversation 
about antibiotic benefits and harms, including discussion about how resistance is 
a potential harm of antibiotics. This thesis also suggested potential methods of 
improving this communication such as patient decision aids, possible public 
health messages, and information about resistance development and decay that 
may assist clinicians’ prescribing decisions. Simultaneous efforts to tackle 
antibiotic resistance from improving its communication in clinical consultations, 
more nuanced public health messages, to its better reporting in medical journals, 
need to be implemented to reduce its global burden and personal and societal 
consequences. 
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Appendix 1. GP consent form and information sheet 
GP Consent Form (consultation recordings)
RO-15543 
Effect of decision aids for acute respiratory infections on the use of antibiotics in 
general practice: a cluster randomised controlled trial 
Investigators: Professor Tammy Hoffmann, Professor Chris Del Mar, Dr Mina Bakhit 
Declaration by participant 
I have read the Participant Information Sheet.  
I understand the purpose, procedures and risks of the research described in the project. 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
I freely agree to take part in this research project as described and understand that I am free 
to withdraw at any time during the project without any negative consequences to me or my 
practice. 
I understand that I will receive a copy of the participant information sheet and this form. 
   Please tick here if you wish to be given a summary of the results of the study once it has 
been completed.  
Please provide the email address you would like this to be sent to: 
Name of Participant (Please print) ________________________________________________ 
Signature of Participant _____________________________ Date  ___________    
Declaration by Researcher†
I have given a verbal explanation of the research project, its procedures and risks and I believe 
that the participant has understood that explanation. 
Name of Researcher† (please print) _______________________________________________ 
Signature or researcher ____________________________      Date  ___________ 
† An appropriately qualified member of the research team must provide the explanation of, 
and information concerning, the research project. 
Note: All parties signing the consent section must date their own signature. 
Appendices 
[176] 
General Practitioner Information Sheet  
(audiorecording of a sample of consultations) 
Full project title: Effect of decision aids for acute respiratory infections on the 
 use of antibiotics in general practice: a cluster randomised controlled trial 
Investigators: Professor Tammy Hoffmann, Professor Chris Del Mar, Dr Mina Bakhit 
You are invited to participate in this study because you have consented to take part in 
the randomised trial of decision aids about antibiotic use in acute respiratory 
infections. This information sheet explains a sub-study that we are conducting at the 
same time as the trial 
Your involvement in this substudy will be the same, regardless of whether your 
practice is randomised to the intervention or control groups of the trial.  
What is the aim of this study? 
This study aims to examine the conversation that occurs between GPs and patients with acute 
respiratory infections and how the decision-making about antibiotic use occurs. In GPs who are 
randomised to the intervention group, we will also examine how decision aids are integrated 
into consultations.  
What does participation in this study involve? 
• At each practice, we would like to audio record 10 consultations between consenting GPs
and consenting patients who have sore throat, acute otitis media, or acute bronchitis.
• For a few days of the trial, until 10 consultations have been recorded, a researcher will be
located in the waiting room of your practice. The researcher will have a handheld audio
recording device and patient information sheets and consent forms. The method of
recruiting patients will vary according to each practice's preference and workflow, with the
options of:
o patients or parents of children who present with one of the target infections will be
invited to participate by their GP at the beginning of the consultation, have the
study explained to them, written consent obtained, and the GP will record the
consultation;
o during these few days, displaying a sign in the reception area advising that patients
presenting with sore throat, cough, or ear infection are invited to participate in a
research study. When patients indicate interest in participating, the researcher who
is present in the practice's waiting room will be able to explain the study to them,
invite consent, and provide patients with the audiorecorder to take into the
consultation with them.
• After the consultation, the researcher will talk with the patients for a few minutes and ask
them a few questions about antibiotics and their confidence in making decision about
antibiotic use.
What are the possible benefits of participating in this study? 
There may not be any individual benefit to you from participating. 
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What are the possible risks of participating in this study? 
Participating in this study is unlikely to have any risks to your physical or psychological 
wellbeing.  
Do I have to take part in this study? 
Participation in this sub-study is completely voluntary. Choosing to participate in it will have 
no impact on your future relation with Bond University or the health system. If you decide to 
participate, you can withdraw your consent and discontinue participation at any time without 
prejudice. You can withdraw your consent from participating in this sub-study and remain 
involved in the main trial.  
What will happen to information about me? 
Data collected in this study will be treated with complete confidentiality and not made 
accessible to any person outside of the research team. Data published or presented from the 
study will not include any information that can identify you or your practice. Data will be kept 
secure, password protected and stored in a secure location at Bond University for a period of 5 
years in accordance with the guidelines set out by the Bond University Human Research Ethics 
Committee.   
Will I receive the results of this study? 
If you would like to receive a copy of the results of this sub-study please tick that box on the 
consent form. 
Who has approved this study? 
This study has been reviewed and approved by Bond University Human Research Ethics 
Committee. This study adheres to the Guidelines of the ethical review process of Bond 
University and the National Statement on Ethical Conduct in Human Research.  
Who can I contact if I have questions? 
If you have any questions about the study, please contact the researcher who provided you 
with this sheet or any of the investigators listed below: 
Dr. Mina Bakhit 0499 461 022 mbakhit@bond.edu.au 
Amanda Murray (Trial co-ordinator)  0474 013 381 cremara@bond.edu.au 
Professor Tammy Hoffmann 5595 2504 thoffmann@bond.edu.au 
Professor Chris Del Mar 5595 5522 cdelmar@bond.edu.au  
 
Thank you for taking time to read about this research study.  
Yours sincerely, 
Dr Mina Bakhit, Professor Tammy Hoffmann, Professor Chris Del Mar 
Centre for Research in Evidence-Based Practice 
Faculty of Health Sciences and Medicine 
Bond University  
Should you have any complaints concerning the manner in which this research is being conducted please contact: 
Senior Research Ethics Officer 
Bond University Human Research Ethics Committee, 
C/o Bond University Office of Research Services 
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Appendix 2. Patient/parent consent form and information 
sheet 
Patient/Parent Consent Form 
RO-15543 
Effect of decision aids for acute respiratory infections on the use of antibiotics in 
general practice: a cluster randomised controlled trial 
Investigators: Dr Mina Bakhit, Professor Tammy Hoffmann, Professor Chris Del Mar 
Declaration by participant 
I have read the Participant Information Sheet.  
I understand the purpose, procedures and risks of the research described in the project. 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
I freely agree to take part in this research project as described and understand that I am free 
to withdraw at any time during the project without any negative consequences to me or my 
child. 
I understand that I will receive a copy of the participant information sheet and this form. 
   Please tick here if you wish to be given a summary of the results of the study once it has 
been completed.  
Please provide the email address you would like this to be sent to: 
Name of Participant (Please print) ________________________________________________ 
Signature of Participant _____________________________ Date  ___________    
Declaration by Researcher†
I have given a verbal explanation of the research project, its procedures and risks and I believe 
that the participant has understood that explanation. 
Name of Researcher† (please print) _______________________________________________ 
Signature or researcher ____________________________      Date  ___________ 
† An appropriately qualified member of the research team must provide the explanation of, 
and information concerning, the research project.  
Note: All parties signing the consent section must date their own signature. 
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Full project title: Effect of decision aids for acute 
respiratory infections on the use of antibiotics in general practice: a cluster 
randomised controlled trial 
Investigators: Dr Mina Bakhit, Professor Tammy Hoffmann, Professor Chris Del Mar 
You are invited to participate in a research study. 
What is the purpose of this study? 
• This study will examine the conversation that occurs between GPs and patients with
acute respiratory infections (sore throat, ear infection, or cough) and how the
decision-making about antibiotic use occurs.
• We also wish to explore patients’ confidence in making decisions about antibiotic
use and their understanding of antibiotic resistance.
What does participation in this study involve? 
• If you or your child has a sore throat, middle ear infection, or an acute cough
(bronchitis), we would like to audiorecord the consultation between yourself and
the GP that you see. The GP also has to provide consent for this to happen.
• After you have seen the GP, one of the research team will talk with you briefly and
ask you a few questions about antibiotics and your confidence in making decision
about antibiotic use. This will take about 5 minutes.
What are the possible benefits of participating in this study? 
There may not be any individual benefit to you from participating. However, your 
participation will benefit the broader community by increasing understanding of 
decision making about antibiotics for acute respiratory infections and how to help 
patients make informed decisions about this.  
What are the possible risks of participating in this study? 
Participating in this study is unlikely to have any risks to your physical or psychological 
wellbeing.  
Do I have to take part in this study? 
Participation in this study is completely voluntary. Choosing to participate in it will 
have no impact on your future relation with Bond University, your GP, or the general 
practice. If you decide to participate, you can withdraw your consent and discontinue 
participation at any time without prejudice. You can withdraw your consent from 
participating at any time.  
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What will happen to information about me? 
Data collected in this study will be treated with complete confidentiality and not made 
accessible to any person outside of the research team. Data published or presented 
from the study will not include any information that can identify you or your child. 
Data will be kept secure, password protected and stored in a secure location at Bond 
University for a period of 5 years in accordance with the guidelines set out by the Bond 
University Human Research Ethics Committee.   
Will I receive the results of this study? 
If you would like to receive a copy of the results of this study, please tick that box on 
the consent form. 
Who has approved this study? 
This study has been reviewed and approved by Bond University Human Research 
Ethics Committee. This study adheres to the Guidelines of the ethical review process of 
Bond University and the National Statement on Ethical Conduct in Human Research.  
Who can I contact if I have questions? 
If you have any questions about the study, please contact the researcher (Dr Mina 
Bakhit) who provided you with this sheet or any of the investigators listed below: 
Dr Mina Bakhit  Tel: (07) 5595 5201 email: mbakhit@bond.edu.au  
Professor Tammy Hoffmann Tel: (07) 5595 2504    email: thoffmann@bond.edu.au 
Professor Chris Del Mar Tel: (07) 5595 5522    email: cdelmar@bond.edu.au  
We thank you for taking time to read about this research study. 
Yours sincerely, 
Professor Tammy Hoffmann  Professor Chris Del Mar Dr Mina Bakhit 
Centre for Research in Evidence-Based Practice, Faculty of Health Sciences and 
Medicine, Bond University  
Should you have any complaints concerning the manner in which this research is being conducted please 
contact: 
Senior Research Ethics Officer 
Bond University Human Research Ethics Committee, 
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Appendix 3. Patient questionnaire 
Patient Questions for nested study 
1. How much effort was made to help you understand your health issues?
0    1  2  3   4 
no effort was made     a little effort was made     some effort was made     a lot of effort was made     every effort 
was made 
2. How much effort was made to listen to the things that matter most to you
about your health issues?
0    1  2  3    4 
no effort was made     a little effort was made     some effort was made     a lot of effort was made     every effort 
was made 
3. How much effort was made to include what matters most to you in choosing
what to do next?
0  1  2  3    4 
no effort was made     a little effort was made     some effort was made     a lot of effort was made     every effort 
was made 
4. After seeing the GP, which option do you prefer? Please check one
a.       Using an antibiotic
b.       Not using an antibiotic
5. Considering the option you prefer, please answer the following questions:
Yes Unsure No 
a. Do you know which options are available to you?       
b. Do you know the benefits of each option?       
c. Do you know the risks and side effects of each option?       
d. Are you clear about which benefits matter the most to you?       
e. Are you clear about which risks and side effects matter most to you?       
f. Do you have enough support from others to make a choice?       
g. Are you choosing without pressure from others?       
h. Do you have enough advice to make a choice?       
i. Are you clear about the best choice for you?       
j. Do you feel sure about what to choose?       
Researcher use 
Study ID: 
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6. Below are some things involved in making an informed choice.
Please show how confident you feel in doing these things by circling from 0 to 4 for 
each item.  
I feel confident that I can: 
a. Understand the information enough
to be able to make a choice
Not at all 
confident 
0 1 2 3 4 Very confident 
b. Ask questions without feeling dumb
Not at all 
confident 
0 1 2 3 4 Very confident 
c. Express my concerns about each
choice
Not at all 
confident 
0 1 2 3 4 Very confident 
d. Let the doctor know what’s best for
me
Not at all 
confident 
0 1 2 3 4 Very confident 
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Appendix 4. Systematic review PROSPERO protocol 
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